Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 27, 2026.

Alzheimer’s Disease as a Membrane Disorder: Spatial Cross-Talk Among Beta-Amyloid Peptides, Nicotinic Acetylcholine Receptors and Lipid Rafts

Camila Fabiani, Silvia S. Antollini

Frontiers in Cellular Neuroscience · 2019 · Review

doi:10.3389/fncel.2019.00309

Abstract

Biological membranes show lateral and transverse asymmetric lipid distribution. Cholesterol (Chol) localizes in both hemilayers, but in the external one it is mostly condensed in lipid-ordered microdomains (raft domains), together with saturated phosphatidyl lipids and sphingolipids (including sphingomyelin and glycosphingolipids). Membrane asymmetries induce special membrane biophysical properties and behave as signals for several physiological and/or pathological processes. Alzheimer's disease (AD) is associated with a perturbation in different membrane properties. Amyloid-β (Aβ) plaques and neurofibrillary tangles of tau protein together with neuroinflammation and neurodegeneration are the most characteristic cellular changes observed in this disease. The extracellular presence of Aβ peptides forming senile plaques, together with soluble oligomeric species of Aβ, are considered the major cause of the synaptic dysfunction of AD. The association between Aβ peptide and membrane lipids has been extensively studied. It has been postulated that Chol content and Chol distribution condition Aβ production and posterior accumulation in membranes and, hence, cell dysfunction. Several lines of evidence suggest that Aβ partitions in the cell membrane accumulate mostly in raft domains, the site where the cleavage of the precursor AβPP by β- and γ- secretase is also thought to occur. The main consequence of the pathogenesis of AD is the disruption of the cholinergic pathways in the cerebral cortex and in the basal forebrain. In parallel, the nicotinic acetylcholine receptor has been extensively linked to membrane properties. Since its transmembrane domain exhibits extensive contacts with the surrounding lipids, the acetylcholine receptor function is conditioned by its lipid microenvironment. The nicotinic acetylcholine receptor is present in high-density clusters in the cell membrane where it localizes mainly in lipid-ordered domains. Perturbations of sphingomyelin or cholesterol composition alter acetylcholine receptor location. Therefore, Aβ processing, Aβ partitioning, and acetylcholine receptor location and function can be manipulated by changes in membrane lipid biophysics. Understanding these mechanisms should provide insights into new therapeutic strategies for prevention and/or treatment of AD. Here, we discuss the implications of lipid-protein interactions at the cell membrane level in AD.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 27, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Biological membranes were, are, and will be complex, dynamic and controversial. Several different theories/models were postulated until the fluid-mosaic model was proposed by. This description of a biological membrane was very well accepted and gave light about membrane structure and membrane function. Although a lot of new information appeared in the following 40 years, the model was able to survive by absorbing some modifications, as it was emphasized by. Table 1 details and compares the most important features of the original fluid-mosaic model membrane and the current vision of a membrane.

Nowadays, a membrane is thought of as an increasingly complex crowded structure of a great variety of lipid and protein arrangements with lateral and transverse asymmetry, variable patchiness, variable thickness, and higher protein occupancy. It is universally accepted that biological membranes behave as barriers separating two fluid media and avoiding contact with each other. But being a physical barrier is not its only or main function. Many of the biochemical reactions essential for cell life (metabolic and signaling reactions involving G-protein coupled receptors as the rhodopsin or muscarinic receptor and ion channels as nicotinic, histamine, GABA or glutamate receptors among others transmembrane proteins) occur in the cell membranes, making them a truly important agent in almost all cellular physiological and pathological processes. These reactions imply molecular communication, which involves protein–protein and also protein–lipid interactions. Lipid membranes are not just a “sea” where proteins are embedded, as it was initially postulated by Singer and Nicolson. Lipids (including fatty acids, cholesterol, endocannabinoids, arachidonic acid metabolites as prostaglandins, leukotrienes, and epoxyeicosatrienoic acids, etc.) are active molecules with important implications. Lipids such as chol, cardiolipin, PIP2 and glycolipids condition the function of several transmembrane proteins, a fact reflected in the thousands of research papers that report the effect of these lipids on protein functions. Here, we will discuss the implications of lipid-protein interactions at the cell membrane level in AD.

Crosstalk of Alzheimer’s Disease Pathogenesis and Lipid Membrane

Alzheimer’s disease is the most prevalent neurodegenerative disorder in the elderly, and is characterized by progressive cognitive decline. The main pathophysiological characteristics include extracellular accumulation of β-amyloid senile plaques and intracellular accumulation of neurofibrillary tangles (hyperphosphorylated microtubule-associated tau protein). A disruption of the cholinergic pathways that contribute to the cognitive impairment of AD patients is described in the cerebral cortex and in the basal forebrain. AD implicates the formation of extracellular insoluble peptides derived from the action of two transmembrane enzymes, a β-secretase (β-site APP-cleaving transmembrane aspartic protease, BACE 1) and a γ-secretase (an imprecise multimeric protein complex), on the membrane-bound APP. Aβ peptides of different lengths, containing 39–42 amino acid residues, are produced. 1–40 Aβ is produced more frequently while 1–42 Aβ is the predominant species in senile plaques. They are amphiphilic peptides with residues 1–28 constituting a hydrophilic domain and residues 29 up to 42 (which correspond to part of the transmembrane domain of APP), a hydrophobic one. Whereas low concentrations of 1–40 Aβ are related to neurotrophic properties, 1–42 Aβ, produced in low amounts under physiological conditions, has a much higher tendency to form oligomers, protofibrils and fibrils, which are the ones that constitute AD brain plaques. The structural-activity relation between these assemblies and the differences between 1–40 Aβ and 1–42 Aβ are under continuous investigation and exceed the aim of this review. Alternatively, APP can be cleaved by another membrane enzyme (α-secretase) between amino acids 16 and 17 of the Aβ region, avoiding Aβ peptides generation and producing a neurotrophic and neuroprotective soluble AβPP (sAβPPα) through a non-amyloidogenic pathway. In neurons, amyloidogenic and non-amyloidogenic pathways compete with each other, jumping between neuroprotection and neurodegeneration. Furthermore, in normal brains, 1–42 Aβ is produced in low picomolar concentrations and, as it will be explained later, these low, non-toxic concentrations have physiological implications in synaptic plasticity and memory, among others. In fact, physiological 1–42 Aβ binds to several target molecules as apoE, the receptor for advanced glycosylation end products (RAGE), serpin–enzyme complex receptor (SEC-R) and nicotinic acetylcholine (nACh) receptors. Thus, although during a person’s lifetime there is a continuous formation of all these peptides, the deregulation of the enzymatic equilibrium with the consequent accumulation of insoluble peptides is characteristic of AD. 1–42 Aβ is the most hydrophobic peptide that forms soluble oligomeric intermediates before aggregating as insoluble plaques with cytotoxic properties in the AD brains. It induces iron and cooper reduction in the brain triggering oxidative stress and damage, it causes calcium homeostasis deregulation probably through lipid perturbation at the cell membrane, and it causes oxy-radicals formation and finally neurodegeneration. Amyloidogenic and non-amyloidogenic pathways are thought to occur in different cellular compartments depending on secretases localization. γ-secretase complex is present in multiple compartments: near 6% in the plasma membrane and the rest in intracellular organelles such as endoplasmic reticulum, late Golgi/trans-Golgi network and endosomes. However, α- and β-secretases are more compartmentalized. α-cleavage occurs at the cell surface. APP is released to the plasma membrane through the secretory pathway and stays there for a short time. Therefore, during this short time, APP is proteolytically processed by α-secretase. Anyway, near 70% of APP is internalized by endocytosis. A fraction of this APP is recycled to the cell surface and another one is degraded in lysosomes. BACE 1 is localized late in the Golgi/trans-Golgi network and endosomes and cleaves APP during the endocytic/recycling cycle; thus, β-cleavage depends on endocytosis and Aβ is produced mainly in the trans-Golgi network during the recycling pathway. Additionally, it was suggested that 1–42 Aβ is produced mainly in the endoplasmatic reticulum whereas 1–40 Aβ is produced in the trans-Golgi network.

APP cleavage by secretases always happens in a membrane, independently of the subcellular compartment. To understand the importance of this fact, it is recommended to read the general commentary by in Frontiers in Physiology titled “Alzheimer’s disease (AD) as a disorder of the plasma membrane,” whereas the author pointed out the implication that the membrane has in the physiopathology of this disease. Several studies postulated that membrane components condition the APP enzymatic processing. Particularly, Chol is a key element in the membrane and it has been related to AD in several ways. studied the minimum lipid requirements of a monolayer for the insertion of APP. They concluded that APP insertion depends on the Chol content, the Chol/PC and the Chol/SM ratios, and the monolayer membrane order. They identified a critical inflection point at near 30% Chol: at a lower ratio APP localizes in the membrane surface mainly in a β-sheet conformation, whereas as this Chol percentage increases, APP can insert spontaneously into the membrane changing its conformation. Consequently, once APP is confined to the interior of the membrane it can perturb the biophysical properties of this membrane and the activity of several transmembrane or associated-membrane proteins. The Chol concentration and Chol location in brain plasma membranes change throughout a person’s life. At early ages, about 87% of the Chol is localized mainly in the inner layer of the brain plasma membrane, but during aging, the percentage of Chol increases in the outer layer losing the initial transmembrane asymmetry and reaching at least 30 mol%, the critical value with respect to APP membrane insertion. In another work, it was suggested that modifications of Chol compartmentation and the equilibrium free cholesterol/cholesteryl esters through acyl-coenzyme A:Chol acyltransferase (ACAT) activation, instead of variations of total membrane Chol, are the determinant of Aβ accumulation and cell dysfunction.

The importance of the amount of Chol for APP insertion leads us to think that APP would probably prefer raft domains. Initial studies in the brain showed that both APP and Aβ reside in detergent-insoluble glycolipid-enriched membrane domains (DIG), suggesting that those domains are the place in the membrane where the APP processing occurs. The non-amyloidogenic pathway through α-secretase is thought to occur in non-raft domains. On the other hand, although there is no consensus about the localization of APP and BACE 1, there is agreement that APP cleavage by β- and γ-secretase occurs in raft domains (see Table 1 for a detailed explanation of raft domains). Experiments in culture cells showed that overexpressed APP and both secretases enzymes localize in Chol-rich domains, and that Chol depletion by Chol synthesis inhibition or Chol membrane extraction resulted in a reduction of Aβ production. Several studies suggest that APP is present in two cellular pools: one in raft domains and another in non-raft domains. concluded that this APP membrane compartmentation explains how the same protein could be processed in two different ways (generating Aβ in raft domains and being cleaved by α-secretase in non-raft domains). Furthermore, they said that although BACE 1 is present in both raft and non-raft domains it needs to be in raft domains to be functional, outside these domains the enzyme is inactive (Figure 1a). That is the reason why, when Chol diminishes, Aβ production also diminishes but increases αCTF (C-terminal fragment) or C83, which is a direct product of α-secretase. Thus, Chol regulates the access of α or β secretase to APP. On the other hand, immediately after this study, a study in human hippocampal membranes showed that the vast majority of APP is located in non-raft domains, while β-secretase BACE 1 is found in two cellular pools: one in raft domains and another in non-raft domains. These authors gave an explanation opposite to the previous one: when Chol diminishes, which is what happens in the membrane from AD patients, BACE 1 increases in non-raft domains and then an enhancement of amyloid peptide production occurs. They concluded that BACE 1 in raft domains corresponds to an inactive pool that needs to relocate to non-raft domains to perform its activity, and that it is the Chol which directly conditions APP processing by “allowing” BACE 1 to exit or not from neighboring domains (Figure 1b). However, they distinguished between a mild membrane Chol reduction (less than 25%), which results in an increase of APP processing, and a drastic membrane Chol reduction (more than 35%), where an overall disruption of membrane integrity occurs concomitantly with a lower Aβ production. Working with primary cultures of rat hippocampal neurons infected with recombinant Semliki Forest virus (SFV) carrying APP, arrived to a different conclusion. They showed that depletion of Chol up to 60–70% did not affect the amount of APPsec (the main processed form of APP in neurons obtained by direct α-cleavage), but drastically decreased the amount of Aβ. Therefore, Chol depletion appears to redirect the APP processing from amyloidogenic processing to non-amyloidogenic cleavage. One possible explanation for this is that the small raft-resident pool of APP and BACE 1 is the active one and that it generates C99 to be processed by γ-secretase. Another explanation considers that the amount of both proteins in rafts is so small that the APP processing by BACE 1 is effective once a clustering of raft domains occurs during endocytosis, meanwhile, in the plasma membrane, APP will be mainly cleaved by α-secretase through a non-amyloidogenesis pathway. Thus, it is possible that APP processing can be altered by membrane lipid composition perturbations. showed that Chol depletion decreases the amount of APP in raft domains and, consequently, the production of Aβ. On the other side, Chol increment as in Niemann Pick type C model cells, causes an APP augmentation in raft domains.

A controversial point is where are secretases located, especially β-secretase, and where they function in the membrane. With respect to γ-secretase, however, there is broad consensus. It is postulated that this enzyme is localized in raft domains confirming that the last step in the generation of Aβ occurs in those domains. These authors postulated that once APP is cleaved by β-secretase, the CTFs (or C99) produced are recruited or sequestered into raft domains where cleavage by γ-secretase takes place. They indicated that ∼20% of BACE 1, less than 5% of APP and more than 70% of CTFs reside in raft domains; and, based on previous work, they assume that all cleavage occurs in these rigid domains.

By magnetic nuclear resonance of C99, identified a short sequence of 5 amino acids (VGSNK) between the extracellular segment and the transmembrane domain that interacts with Chol, probably through hydrogen bonds. These authors recognize that although C99 is in raft domains, APP, which has the same loop, localizes mainly in non-raft domains, concluding that one possibility is that APP and C99 have different affinities for Chol. This Chol interaction site is also present in Aβ peptides, thus explaining the reported Chol-Aβ peptides interactions that trigger oligomerization, fibrillization, etc. which will be discussed below.

Chol is not only crucial for APP processing in the membrane by compartmentalizing the location of both APP and secretases, but also for modulating the secretases activity. Briefly, Chol positively modulates BACE 1 and γ-secretase activities, and negatively modulates α-secretase. In lysates from human brain and in cultured cells, a certain amount of Chol stimulated β and γ-secretase activities, but at 20 μM Chol γ-secretase activity was inhibited. It is probable that high Chol can directly stabilize the activities of the enzymes to the maximum level in the correct lipid domain or can reduce enzymes degradation increasing Aβ production. Furthermore, APP processing can be modulated by Chol conditioning membrane biophysical properties. For example, substitution of Chol by lanosterol or polyunsaturated free fatty acids (PUFAs) induced an increment of membrane fluidity, which was related to an enhancement of α-secretase activity.

Aβ Relationship With and Implications on Cell Membrane

Chol is also important for Aβ peptide action/effect. Aβ peptide can adopt different conformations: a random-coil conformation in aqueous solution, an antiparallel β-sheet in the core of the amyloid plaques, and an α-helix in membranes containing Chol. It can exist as monomers, oligomers or as amyloid fibrils. Several studies indicate that Chol directly binds to APP as was described above, and also to C99 and monomeric Aβ peptides, to oligomers, to aggregates, and to fibrils. Considering that the mechanism by which Aβ produces brain dysfunction in AD patients is still unknown, these evidences turned the view of Aβ peptides pathogenesis from extracellular plaques (the “amyloid theory”: extracellular amyloid plaques are the responsible for cell death;;;; ) to Aβ peptides interaction with the plasma membrane. A more recent explanation indicates that Aβ monomers or small oligomers are responsible of neuronal death rather than amyloid plaques as it was previously thought. Furthermore, amyloid plaques reduce neuronal death by sequestering the dangerous Aβ monomers/small oligomers (Figure 2). This explanation is contrary to a previous one that considered that Aβ aggregation in β-sheet conformation, which will finally end as neurotoxic fibrils, is reduced by Aβ insertion as α-helix after interaction with Chol-containing membranes. They showed that both 1–40 Aβ and 1–42 Aβ peptides prefer Chol enriched LDM and that while in healthy humans the amount of the former peptide is more than twice the second one, the progression of 1–42 Aβ deposition runs in parallel with an increase of this peptide in LDM domains. The authors concluded that Chol enrichment would be beneficial for reducing fibrils, a membrane condition opposite to the one found in AD brains that show a drastic decrease of membrane Chol content and hence do not have the needed conditions for Aβ insertion, favoring the dangerous pathway of Aβ aggregation. In the case of AD patients, isolated brain membranes showed a significant decrease in membrane Chol, disfavoring the insertion of Aβ into the membrane. Thus, Aβ remains in the membrane surface with a great tendency to aggregation and, ultimately, to plaque formation. By confocal laser microscopy and fluorescence anisotropy, it was shown that 1–42 Aβ peptides interact with raft domains and that there is an inverse correlation between Chol content and membrane perturbation. It was further indicated that a Chol increment decreases amyloid-induced membrane perturbations at lipid rafts by altering the physicochemical properties of the domain. Specific interactions that induce changes in the lipid bilayer conducing to membrane disruption were described between lipids and Aβ peptides. Different kinds of interactions were proposed in the last few years. performed studies of Aβ interactions with model biomimetic membranes and showed that immediately after peptide addition, membrane fluctuations/morphological changes occur. They suggested that both Chol levels and lipid composition affect how Aβ oligomers interact with the membrane. X-ray diffraction studies of the interaction between a 25–35 Aβ peptide and anionic membranes enabled the identification of immiscible Chol plaques when more than 30 mol% Chol was added. The peptide interacts with the bilayers sequestering more Chol molecules into the plaques and, hence, decreasing the amount of Chol in the membrane.

Chol is not the only important lipid in the Aβ-membrane interactions, there is also GM1, which is a resident lipid of raft domains. High Chol levels facilitate gangliosides clustering, which is postulated to modulate Aβ oligomerization. These clusters interact with Aβ peptides in a concentration dependent manner inducing Aβ aggregation in β-sheet rich structures with a high Aβ/ganglioside relationship. The binding of Aβ to a GM1 cluster favors a conformation transition that depends on the protein density of the membrane. At low peptide/lipid ratios a transition from random coil to α-helix conformation occurs, whereas at high peptide/lipid ratios a β-sheet rich structure appears, which ends in fibrils formation. Significant alterations in the lipid composition of raft domains in frontal cortex of AD patients were described. A detailed study of the lipid composition of DRM from temporal and frontal cortex of AD brains indicated that there was an increment of GM1 and GM2 in both areas of the brain studied. This difference, which was considered an early event in the progression of AD, was not observed between samples from brains of different ages or gender. Other studies agree with an age-dependent high-density GM1 clustering in synaptosomes and specific Aβ peptides and GM1 complexes in early AD brains. GM1-Aβ interactions (GAβ) were described in the brain and associated with AD pathology. Thus, GM1 is postulated as the seed for the formation of amyloid fibrils, and several studies considered raft platforms as the site where these interactions happen. showed that the interaction and aggregation of the peptide enhances lipid phase separation because of the GM1 relation with Aβ aggregates. A two-step phase was postulated to occur in membranes of AD patients: at early stages the proportion of GM1 in raft domains increases accelerating Aβ plaques formation and triggering a gradual raft disruption and perturbation of the cellular function that involves these membrane domains; at a later stage, there is also a decrement in Chol content which prevents Aβ aggregation and increases neurotoxicity. A more detailed study of the mechanism of Aβ interaction with GM1 indicates that Aβ oligomers, which have increased hydrophobicity compared to Aβ monomers, primarily bind to GM1 initiating progressive alterations such as membrane biophysical and ion permeability perturbations that end in the well-known synaptotoxic effects of Aβ.

Although all data points to a direct implication of gangliosides on Aβ oligomerization, a ganglioside-independent Aβ oligomerization mechanism was also observed, suggesting that other lipid components or carbohydrates in raft domains would be also implicated.

One important consequence of these raft domains/Aβ peptide interaction is the occurrence of Aβ peptide aggregation and Ca+2 channels formation in raft domains. In hippocampal cell membranes this process was related to neurotoxicity. identified a Chol binding domain in a 20–35 fragment of 1–42 Aβ, which is also present in other peptides with high Chol affinity. Interestingly, although both APP and 1–42 Aβ interact with Chol, they have distinct binding domains [17–40 Aβ for APP and 20–35 Aβ for 1–42 Aβ]. By physicochemical and in silico experiments, it was demonstrated that this 20–35 Aβ domain forms oligomeric Ca2+ channels in the plasma membrane in a Chol dependent manner. The high interaction with Chol of this 20–35 Aβ domain triggers the helix to an adequate tilted orientation inside the membrane, which allows accurate peptide-peptide interactions and the formation of the circular channel. This oligomeric channel is formed by eight 20–35 Aβ subunits and eight Chol molecules, with a pore size and an external diameter of 1.46 and 4.4 nm, respectively. The formation of these channels could help explain the neurotoxic properties of 1–42 Aβ (Figure 2). Similar in silico studies performed with 1–40 Aβ showed that the interactions between Chol and peptide are different to those observed with 1–42 Aβ. Since the initial proposal of the existence of transmembrane ion channels formed by Aβ peptides, lots of studies deepened in the “β-amyloid calcium channel hypothesis”. The first step for this ion channel formation must be the contact between the peptides and the membrane. It was demonstrated that both the lipid composition of the outer membrane and the structural conformation of the Aβ peptide are crucial for this interaction. In solution, it was possible to find Aβ as β-sheet, α-helix or random coil conformations, being the conformational balance dependent on its concentration. It is postulated that the presence of certain lipids can shift the equilibrium to one preferred conformation. Particularly, it was demonstrated that negatively charged lipids take contact with the peptide by specific electrostatic interactions. Aβ selectively recognizes and accumulates on GM1-rich membrane domains, and Aβ insertion into the membrane is critically dependent on the Chol/phospholipids ratio, as it was detailed above. More recent works showed that the formation of Ca2+ pores (“annular protofibrils,” ) in the plasma membrane is a mechanism dependent on both gangliosides and Chol. As it was described above, amyloid monomers or soluble oligomers interact with a ganglioside at the cell surface, with a specificity that responds to a ganglioside-binding domain for each amyloid protein (common amino acid residues at specific locations, with specific variations for each ganglioside), being the Ca2+ pores significantly diminished in ganglioside deprived cells. Based on this “calcium-channel hypothesis” of the AD, a chimeric peptide formed with a minimal ganglioside-binding domain of α-synuclein and two contiguous His residues as in 1–42 Aβ avoid pore formation by 1–42 Aβ. Treatment of WT 5XFAD mice with a sialic-specific lectin (LFA, Limax flavus agglutinin) significantly reduced amyloid depositions in the brain, probably by interfering with the binding of amyloid peptides to gangliosides. Furthermore, showed that different oligomer conformations can perturb Ca2+ cell-permeation by both a channel-independent mechanism as annular protofibrils, or by a channel-dependent one (through NMDA-R and AMPA-R).

Aβ peptides that stay in the membrane surface are in a β-sheet conformation, and once inside the membrane they turn their conformation to an α-helix. Other studies suggested that 1–40 Aβ interacts with the membrane in two sequential steps. The first one involves the formation of a pore-like structure and membrane permeation, and the second one involves subsequent growth of aggregates with fibril formation and lipid clustering around the fiber which implies lipid extraction, membrane fragmentation, and loss of membrane integrity.

Recently, described more in detail the interactions between cell membranes and Aβ peptides. Those interactions depend on peptide conformation: structural oligomers are imbibed in the outer hemilayer of the membrane triggering more Aβ addition and further elongation; on the other hand, early labile oligomers in equilibrium with monomers are incorporated as monomers deeply in the membrane coming up to the inner hemilayer, whereas Aβ organization leads to pore formation.

A study of the changes induced by 1–42 Aβ on the morphology and the mechanical stability of model membranes with different Chol content indicates that Chol drives 1–42 Aβ toward rafts domains and that at high Chol concentration the presence of the amyloid peptide did not alter any membrane property, thus assigning a protective effect against membrane destabilization by 1–42 Aβ to the presence of Chol. Recently, deepened this idea. They observed that 1–42 Aβ has a higher affinity for liquid-disordered (ld) than ordered (lo) phases, confirming previous results. They concluded that the fraction of Aβ in lo domains, probably the functionally important one, might be smaller. While in a lo phase 1–42 Aβ induces practically no changes in the lipid packing, a significant perturbation of the lipid packing by its presence was observed in a ld phase. They focus on the presence of GM1 as a crucial lipid. In ld phases without GM1, the peptide penetrates and messes up the neighboring lipids. However, in the presence of GM1 the peptide interacts with the headgroup of several GM1 promoting a condensing effect and an increased lipid packing and decreases Aβ penetration. The presence of GM1 could affect the line tension between lo and ld domains which in turn affects the kinetics of domains formation, growth, shape and size. Thus, although it cannot be discarded that the functional peptide, or at least a minority of it, binds directly to lo domains, the authors suggested that the fibrillation of Aβ peptides in raft domains is the consequence of a reorganization modulated through Aβ peptides in non-raft domains.

Not only specific lipid raft characteristics are necessary for Aβ insertion into the membrane, but also its insertion has consequences on the membrane. Several studies analyzed the membrane biophysical perturbations caused by Aβ interaction, which could be considered the first step of its biological effect. A decrease in the fluidity of mouse brain membranes, human lymphocyte membranes and membranes from rat cortex, hippocampus and striatum was observed in the presence of 25–35 Aβ and 1–40 Aβ, and in all cases the effect was dependent on peptide concentration. Low concentrations of Aβ significantly perturb membrane fluidity by specifically altering the acyl-chain mobility of brain membranes, an effect dependent on peptide length, with almost no effect at the polar head groups. Lately, it was observed that monomeric 1–40 Aβ has no effect on membrane fluidity, while oligomeric forms do. Contrary to these results, by exposition of hippocampal neurons to nanomolar concentrations of Aβ oligomers for 24 h we could not observe changes in membrane fluidity tested with three different fluorescence probes. showed that membrane perturbation by Aβ is a consequence of Aβ complexing with GM1; thus, it is possible that in our experiments the cell membrane did not have the correct GM1/Chol relationship. A previous study of the interaction of 1–42 Aβ with planar bilayers had already demonstrated that the Chol content is directly correlated with Aβ assembly on the membrane surface, that during this process membrane changes occur, and that all this process is governed by lipid bilayer composition. Thus, membrane lipid environment modulates Aβ production and at the same time Aβ causes a membrane perturbation that positively feedbacks its own production. Moreover, Aβ insertion into the membrane not only potentiates Aβ production but also unspecifically activates a variety of membrane processes which could eventually end in neuronal cell death. 25–35 Aβ peptide interacts with phospholipids through electrostatic interactions favoring peptide aggregation which causes perturbations at the lipid-water interphase of the membrane. Mass spectroscopy studies showed that Aβ inserts into model membranes containing Chol, but not in the absence of Chol. This study also indicated that the membrane insertion is initiated by the C-terminus of the Aβ peptide which has the hydrophobic domain.

Brain membranes from middle aged mice were more susceptible to Aβ perturbations than membranes from aged mice; and in vitro studies showed that a decrease in membrane Chol content enhanced Aβ effect, while an increase in membrane Chol strongly decreased the perturbation effect, suggesting that Chol protects neuronal membranes from Aβ perturbations and neurotoxicity. However, they also observed in vivo that a reduction of Chol levels by approx. 30% by treatment with lovastatin (HMG-CoA-reductase inhibitor) resulted in moderated membrane alterations without acyl chain flexibility perturbations and reduced Aβ bulk fluidity perturbation. A possible explanation is that Chol membrane modification involves different membrane Chol pools with different sensitivity for Aβ perturbations whether it is in vitro or in vivo, with the one at the membrane acyl-chain being the most receptive.

Another important consequence of an enhanced Aβ production linked to lipid membrane is oxidative stress with an excess of lipid peroxidation and increased lipid susceptibility to oxidative damage, which exacerbates Aβ toxicity in the membrane. It is reported that Aβ prefers to interact with membranes with high oxidatively damaged phospholipids, particularly in raft domains, and that these membranes promote misfolding and aggregations of Aβ peptides into fibrils, whereas the misfolded peptides promote more oxidative damage in the membrane, conducing to a positive feedback. Aβ increases 4-hydroxy-2-nonenal (HNE) production which promotes oxidative damage and also induces Aβ to form β-structure and amyloid fibrils.

Even though it is not a topic of interest for this review, it is important to remember that just as Chol is a crucial lipid molecule for Aβ processing and Aβ membrane effects, the round trip is also valid since Aβ has an impact on Chol homeostasis. This ultimate effect suggests that Aβ down-regulates Chol content and also raft content. Thus, the peptide behaves as a Chol sensor: when there is high Chol content in a membrane, the amyloidogenic pathway is favored and, thus, an enhancement takes place in Aβ processing, which in turn reduces both Chol uptake and biosynthesis, following up a negative feedback mechanism.

Crosstalk Between Amyloid Hypothesis and Cholinergic Hypothesis

The basis of AD pathogenesis is still controversial today, even though several hypotheses try to explain it, such as the Aβ amyloid cascade, the hyperphosphorylated microtubule-associated tau, abnormalities of the cholinergic system, oxidative stress, etc. Even though the amyloid hypothesis is the most popular explanation for the mechanism of AD, it fails to explain several aspects of this multifactorial etiopathology. In addition, until now, the majority of clinical trials conducted to diminish the amount of Aβ did not give good results. Although these failures are not enough to discard the amyloid hypothesis (see for example ), attention is now focused on the cholinergic hypothesis since it became the main therapeutic strategy for this disease (Figure 2). As we will work out in the following paragraphs, these two hypotheses are highly linked.

The cholinergic system involves two families of receptors, nAChR and muscarinic acetylcholine receptors (mAChR). Although both types of receptors are related with cognitive processes and are affected in AD, only the relation between nAChR and AD has been largely studied.

The nAChR is an integral membrane protein that belongs to the Cys-loop superfamily of ligand-gated ion channels. The binding of its natural agonist acetylcholine triggers a conformational change that ends in the opening of a channel and the flux of positive ions across the membrane, causing membrane depolarization and a subsequence intracellular cascade of events. The nAChR presents a pentameric arrangement, with each subunit having a large N-terminal extracellular domain, four transmembrane segments (M1–M4), a small cytoplasmic domain between M3 and M4, and a short C-terminal extracellular domain. To this day, 16 different nAChR subunits (including: α1-7, α9-10, β1-4, γ, δ, and ε) that form homologous and heterologous receptors with distinct structures, functions and locations are known. The muscle-type nAChR of the electric organ of Torpedo, first receptor described and still the prototype of the family, is formed by α12β1δγ (similar to embryonic muscle nAChR of vertebrates, which change to α12β1εγ in adult). Two receptor subtypes are highly expressed in the central nervous system: the heteropentamer α4β2 nAChR and the homopentamer α7 nAChR. The latter is particularly important in AD. It is present in high density in the striatum, thalamus, neocortex, and limbic system suggesting a central role in normal cognition and, hence, in age-related cognitive decline. It was shown that α7 nAChR is important for growth, development and aging, regulating the plasticity of the neural circuit, neuronal differentiation, proliferation, apoptosis and clearance of aged neurons. The levels of this receptor change during development and adult stage, and in AD patients, they decrease significantly.

Activation of the α7 nAChR opens a high permeability Ca++ channel that consequently activates voltage-dependent Ca++ channels and triggers an intracellular signaling cascade through activation of a protein kinase. In the case of activation of presynaptic α7 nAChR, the final event is the fusion of vesicles loaded with neurotransmitters (glutamic acid, norepinephrine, acetylcholine, dopamine and GABA) to the presynaptic membrane and the massive release of these neurotransmitters to the synaptic cleft. Postsynaptic α7 nAChR depolarize the postsynaptic membrane and participate in signal transduction. ACE metabolizes acetylcholine after its release to the synaptic cleft ending the cholinergic stimulus.

The cholinergic hypothesis of AD focuses on the fact that in brains of AD patients there is a decrease in the total amount of nAChRs, which is an outcome of progressive death of forebrain cholinergic neurons with an extended cholinergic presynaptic denervation. This is considered a consequence of enhanced Aβ production. observed that in the remaining cholinergic neurons there was a higher amount of nAChR, which suggests a possible compensatory mechanism. Many efforts were performed to ameliorate this loss. However, current approved pharmacological agents, such as physostigmine, tacrine, donepezil, rivastigmine and galantamine, are targeted to inhibit ACE function increasing the amount of acetylcholine at the synapse cleft and ameliorating the clinical symptoms of AD without halting the progress of the disease.

The affinity of α7 nAChR for 1–42 Aβ is in the low picomolar concentration, a range estimated to occur in healthy brains, while the affinity of α4β2 nAChR for 1–42 Aβ is between 100 to 5000 times lower; thus, it is expected that both α7 nAChR and 1–42 Aβ could associate under physiological conditions. hypothesized that under physiological conditions a positive feedback mechanism occurs: synaptic activity induces Aβ release that acts as an endogenous ligand and modulates α7 nAChR, which in turn induces release of neurotransmitters and enhances synaptic plasticity and memory. Under pathological conditions, abnormal accumulation of Aβ (nanomolar concentration,,;; ) induces a negative feedback mechanism which implies inhibition and internalization of α7 nAChR, leading to synaptic dysfunction and memory loss. The Aβ-α7 complex influences tau hyperphosphorylation and its internalization leads to plaque formation.

It is thought that the soluble form of Aβ interacts with α7 nAChR with apparently high affinity regulating its function. However, there is no consensus about the nature and consequences of this interaction. While several studies propose an agonist-like effect for presynaptic nicotinic receptors, others propose an inhibitory action, and others a concentration-dependent relationship with a stimulatory effect at picomolar Aβ concentration and an inhibitory effect at high nanomolar Aβ concentration. The variability between all the performed studies is so large in terms of in vitro and in vivo models, Aβ concentrations and Aβ preparations/conformations, and other conditions, that it is difficult to find a rule for the data obtained. gave a possible explanation for these inconsistency centered in a different Aβ effect on pre or postsynaptic receptors. Aβ induces a rapid stabilization of an inactive/desensitized state of postsynaptic receptors, resulting in an antagonist effect, and a slower desensitization of presynaptic receptors resulting in an agonist-like effect. The authors pointed to differences in the lipid microenvironment of the pre and postsynaptic α7 nAChR for these different desensitization rates. Presynaptic terminals have abundance of raft domains, and experimental disruption of these domains dramatically attenuates Aβ evoked α7 nAChR currents. With respect to the concentration-dependent effect, it is important to take into consideration that in a normal central nervous system 1–42 Aβ is found, although at low picomolar concentrations. Under this condition, it is postulated that Aβ exerts a positive effect on synaptic plasticity and memory formation. However, in a pathological condition, Aβ cannot exert its physiological function and hence a feedback mechanism induces more Aβ production, leading to an enhancement of the peptide with the subsequent reduction of α7 nAChR with Aβ removal and synaptic alteration and memory loss.

Interaction of Aβ with α7 nAChR increases Aβ internalization and accumulation in lysosomes causing an excessive intraneuronal 1-42 Aβ accumulation. The majority of the amyloid plaques proceed from the lysis of degenerated, Aβ-overburdened neurons. Additionally, the formation of the Aβ-α7 nAChR complex may influence the membrane lipid and membrane protein organization. At the same time, the internalization of the Aβ-α7 nAChR complex triggers an upregulation of the α7 nAChR and magnifies the toxicity of the pathology (Figure 2). In AD patients and preclinical AD models, a high expression of α7 nAChR was described. Chronic exposure to Aβ enhances the expression of α7 nAChR in neuron and glia cells. Also, an age-dependent increase of cell surface α7 nAChR was observed in 5xFAD mice, a model that rapidly develops amyloid pathology. Several studies contributed to this hypothesis. Treatment of PC12 cells with 1–42 Aβ increased cell surface α7 nAChR, suggesting that the peptide induces translocation of the receptor toward the plasma membrane. They observed that the agonist nicotine prevented Aβ induced cell death, whereas the competitive antagonist α-bungarotoxin potentiates the peptide effect, indicating that α7 nAChR plays a role in protecting neuronal cells from Aβ 1–42 peptide. Contrary to this, concluded that upregulation of α7 nAChR induced by Aβ is necessary to mediate peptide neurotoxicity, both in hippocampal neurons and differentiated cholinergic SH-SY5Ycells. α7 nAChR function, which is exacerbated by its upregulation, may be necessary for the toxicity of Aβ aggregates; this effect was prevented by α7 nAChR inhibition or deletion. Previous studies showed that the blockade of α7 nAChR significantly ameliorated attentional deficits. Likewise, the deletion of α7 nAChR gene was correlated with an improvement in synaptic plasticity and a reduction in cognitive deficiency. Two possible cytotoxic α7 nAChR-mediated mechanisms were proposed: one considers that the α7 nAChR increment in the membrane conduces to a high calcium permeability, which could be the ultimate responsible for cell toxicity, and the other that the high Aβ-α7 nAChR complex internalization and intracellular accumulation leads to neurotoxicity. Thus, while several studies point to α7 nAChR activation as a beneficial treatment, others suggest that a function inhibition for a beneficial effect is necessary.

A different hypothesis about Aβ and α7 nAChR relationship was postulated by. They concluded that Aβ does not bind directly to α7 nAChR but to the lipids of the plasma membrane, and that the perturbation of the structure or fluidity of the lipid microenvironment of the receptor could be the responsible for toxicity through an alteration of the receptor function. Their conclusion is supported by previous evidence that showed that Aβ binds strongly to lipids. We will return to this issue later.

We here described the most relevant information about the interaction between Aβ and α7 nAChR, and its final consequences, focusing on the events that occur through the membrane. However, not only the interactions between Aβ and α7 nAChR are important. Other proteins that interact with α7 nAChR including Lynx proteins, NMDA-receptors and the Wnt/β-catenin pathway are important as well. All those interactions that modulate receptor function are specifically altered in AD and can lead to differences in the clinical effect of nAChR ligands in AD. It is also important to take into account that there is an internal cascade of signaling downstream α7 nAChR activation that involves several other active molecules, such as glycogen synthase kinase-3β (GSK-3β), phosphoinosite 3-kinase (PI3K)-Akt, Wnt and the mitogen-activated protein kinase (MAPK) signaling pathway, which are also altered in AD (see for a further explanation).

The last step in cholinergic signaling is the degradation of acetylcholine by the enzyme ACE to end the synaptic transmission. ACE is a globular non-transmembrane protein that can exist in different molecular forms, depending on the splicing of the ACE gene. Although all ACE molecular forms and variants have similar catalytic activity, they also have other non-catalytic, non-classical functions, which depend on the multiple molecular forms of this enzyme and on cell types and cellular compartments. In non-neuronal tissues, ACE regulates cell proliferation, differentiation, apoptosis and cell–cell interaction, which is important to take into consideration when ACE inhibitors for AD are designed. ACET is the predominant form in central nervous system, which has a C-terminal α-helix peptide of 40 amino acids named T peptide. Through disulphure bondings between these peptides they can be found as homodimers and homotetramers of ACET. Also, the T peptide binds to hydrophobic proline-rich domains of membrane anchoring-proteins (like collagen-like Q subunit in NMJ and proline-rich membrane anchor, PRiMA, in the central nervous system; ). In the central nervous system, the majority of ACE is found as tetrameric ACET (G4) bound to PRiMA, which constitute the functional units at cholinergic synapse. PRiMA could bring the membrane-bound ACE together with other proteins in specialized membrane areas, such as raft domains, specifically with α7 nAChR at basal forebrains cholinergic neurons. A significant proportion of ACET is effectively located in raft domains through a Chol-binding domain of 13 amino acids of PRiMA (a CRAC, Chol recognition amino acid consensus, sequence), and Chol depletion or mutations at this domain reduced the lipid raft-PRiMA association. A diminution of ACE activity in the cerebral cortex and other areas in AD patients was described, being the G4-PRiMA complex the ACE form markedly altered, whereas the ACE monomeric form was almost preserved. Interactions of PRiMA subunit with presenilin 1 (PS1, the catalytic subunit of γ-secretase), which is an aspartyl protease that cleaves substrates inside membrane, were described to occur in raft domains. This interaction could explain, in part, the cellular release of ACE through a shedding mechanism that was postulated to involve a metalloprotease. Furthermore, a direct relationship between PS1 and ACE was observed, with an overexpression of ACE related to higher levels of PS1, ACE knockdown leaded to decreased PS1 and a mutated PS1 was related with decreased ACE in the brain. At the same time, it was also observed that ACE inhibits AβPP processing through γ-secretase, perhaps, acting as an inhibitor of the secretase by interacting with PS1. In AD, ACE activity is diminished and hence impedes its potentiality to modulate γ-secretase.

Interactions of ACE with Aβ are important in AD, as the peptide alters several ACE properties such as its pH optimum and inhibitor sensitivity, making Aβ even more neurotoxic. Moreover, ACE was detected in amyloid plaques evidencing the high affinity between both molecules and suggesting that ACE could promote Aβ aggregation. Even more, in some cerebral areas of AD patients almost all ACE is in these complexes. The binding between Aβ and ACE occurs at the ACE peripheral anionic site (PAS); ACE inhibitors that bind to the anionic site (i.e., propidium), as well as antibodies against it, significantly reduce fibril formation. Although the ACE catalytic domain does not participate of this interaction, new compounds with a dual action (blocking PAS and catalytic site) are being designed, looking for the prevention of fibril aggregation with the aim of reversing the progression of the disease and, at the same time, inhibiting acetylcholine degradation to ameliorate the symptomatology.

Furthermore, a negative relationship between APP and ACE was observed, as an overexpression of APP repressed ACE transcription with reductions of both ACE levels and ACE activity. A similar negative regulation was observed between APP and PRiMA; however, it is not clear if there is a direct downregulation by APP or if this diminution is a consequence of decreased ACE levels. The authors proposed that this ACE downregulation could be a novel neuroprotective function of APP.

nAchR and Membrane Lipids

As we said in the previous section, there are several nAChR subtypes depending on the individual pentameric arrangement. Summing up, all nAChR have two well defined structural domains: the neurotransmitter-binding site extracellular domain and the transmembrane domain containing the ion pore. Whereas the extracellular domain is the site where the agonists or different activators/inhibitors bind, the transmembrane region, besides having the ion pore, exhibits extensive contacts with the surrounding lipids through structural motifs remarkably conserved along phylogenic evolution. It is well known that a correct allosteric coupling between both domains is crucial for nAChR function, strongly dependent on its surrounding lipid, which modulates the relative proportion of nAChR in its resting or desensitized states. The most studied nicotinic receptor is the muscle nAChR, which is not only the paradigm of all other nAChR but also of the entire cys-loop superfamily. In the following paragraphs we will discuss the relationship between distinct lipids or raft domains and the muscle nAChR, knowledge that can be extended to other members of the family, in particular to α7 nAChR.

Several years ago, described a layer of immobilized lipids that encircle the muscle nAChR with characteristics different from those of bulk lipids. Subsequent studies assigned an important role to these bounded lipids on muscle nAChR. The presence of both Chol and negatively charged lipids in the nAChR-lipid microenvironment is necessary to stabilize the nAChR in a functional conformation. However, there is no consensus about if it is the entity/identity of the lipid itself or the fluidity that each lipid confers to the membrane the responsible of this role. In spite of this controversy, the importance of a proper lipid microenvironment for muscle nAChR becomes clear when highly hydrophobic molecules, such as free fatty acids or steroids, perturb nAChR function through the membrane localizing at the lipid-nAChR interphase. Working with reconstituted Torpedo nAChR, distinguished two different populations of lipids in the nAChR-lipid microenvironment region: annular and non-annular lipids. Annular lipids interact with the protein in a relatively less specific manner with a fast rate of exchange with bulk lipids. Contrarily, non-annular lipids are in close contact with the protein, probably in between α-helix transmembrane segments or subunits, and can be associated to lipid binding sites with a slow exchange rate with bulk lipids. We identified the same two types of lipids in native Torpedo membranes. The entity/identity of non-annular lipids are considered crucial for nAChR function; in the case of annular lipids the biophysical characteristics are more relevant. This is in concordance with other studies that assigned several roles to the lipids in a membrane, two of the main ones being: a collective one, in which they form a viscoelastic lipid “solvent” with the above-mentioned heterogeneities; and an individual one as signaling molecules.

Two annular lipids that are of particular interest are negative lipids and SM. With respect to the requirement of negative lipids, PA is particularly of interest. The segregation of PA domains containing nAChR and the stabilization of a functional conformation of the receptor by PA were described. SM showed moderated affinity for the nAChR but it is important for proper nAChR stability in the membrane. Its deficit affects the efficiency of the nAChR assembly process and the nAChR targeting to the membrane and increases the rate of turnover. Moreover, SM is important for membrane biophysical properties as it is asymmetrically distributed between both membrane hemilayers and it is one of the main actors of lipid raft domains, being both aspects that impact on nAChR.

A separate paragraph is for Chol, a key lipid for nAChR. This lipid molecule can be found in every region of a membrane: as a bulk, annular or non-annular lipid. In the first two cases, it probably plays an important function conditioning the physical properties of the environment, mainly because of its participation in raft domain formation and in the maintenance of the asymmetrical membrane condition. As a non-annular lipid, the occurrence of allosteric binding sites is postulated. It was suggested that the binding domain for Chol is at the nAChR lipid-protein interface, taking contact with the transmembrane subunits αM4, αM1, and γM4; other studies identified interactions of Chol with the transmembrane segments M1, M3, and M4 of each subunit. By fluorescence quenching and energy-transfer measurements of T. californica reconstituted membranes, sites accessible to Chol but not to phospholipids were identified. Using Molecular Dynamics simulations of the nAChR structure, identified 15 Chol binding sites, large hydrophobic intersubunit and intrasubunit gaps. The location of Chol molecules at these sites improved nAChR stability; and in the case of intrasubunit sites, occupation of these sites by Chol precludes the nAChR from collapsing. A recent study using coarse-grained molecular dynamics simulations suggested that while long n-3 chains (in this case, docosahexaenoic acid, 22:6) have a high propensity for annular and non-annular sites, displacing Chol and occupying sites even deeper within the bundle, shorter n-6 chains do not displace Chol from non-annular sites as efficiently as long n-3 chains.

Considering the intimate and close relationship between Chol and the muscle nAChR, studies looking for a consensus about specific Chol domains in the nAChR subunits were performed. A CRAC sequence in a region immediately adjacent to the M1 transmembrane domain of all the subunits of the muscle nAChR was identified. These sequences are located exiting the membrane bilayer, which suggests that they are probably not good partners for Chol in the hydrophobic membrane environment. However, a novel Chol recognizing domain was identified by in silico studies, a sequence opposite to a CRAC one (inverted CRAC or “CARC” sequence) at M1, M3, and M4, which is located inside the membrane and is highly preserved in the evolutionary scale, from prokaryotes to humans. These in silico results were also experimentally confirmed. Furthermore, the authors concluded that a CARC sequence generally exhibits more affinity for Chol than a CRAC one, and that it is of high affinity, lipid specific, and saturable.

Chol not only conditions nAChR function but also its stability in the plasma membrane. There are some controversies about how the nAChR is organized in the membrane. At the NMJ, supramolecular aggregations of nAChRs (micron-sized two-dimensional clusters) are postulated to occur in Chol-rich lipid microdomains, together with several postsynaptic proteins including rapsyn, MuSK and Src-family kinases. Chol would stabilize NMJ and promote its maturation. Depletion of cell-surface Chol produced a marked alteration of the organization of the nAChR. One hypothesis for this situation is that after an agrin (extracellular heparan sulfate proteoglycan that aggregates nAChRs on cultured myotubes) stimulus, nAChR and MuSK translocate into raft domains where nAChR clustering occurs, as raft domains concentrate the agrin/MuSK signaling, nAChR and rapsyn. Disruption of these microdomains by Chol depletion inhibits agrin stimulation and formation and maintenance of nAChR clusters. A contemporary study suggested that agrin causes the translocation of nAChR into raft domains, which is in agreement with the mentioned hypothesis. A slightly different hypothesis indicates that agrin does not reclute nAChRs into raft domains, as they are already in those domains independently of agrin activation, but it triggers the coalescence of raft domains conducing to nAChR clustering and it is also responsible for its maintenance, as Chol is necessary for all this process. A previous study supports this hypothesis where the authors observed that nAChR subunits and rapsyn are cotargeted in the exocytic pathway to the cell surface inserted in Chol-rich microdomains. Furthermore, Chol depletion affects the maintenance of the nAChR in the plasma membrane by several mechanisms. Treatments of cells with methyl-β-cyclodextrin, which extracts Chol from the membrane, enhanced nAChR internalization by endocytosis with a marked decrease of the number of nAChR domains, concomitantly with a gain-of-function of the remaining nAChR. Furthermore, chronic treatments with mevinolin, an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase and hence of Chol synthesis, inhibited the trafficking of the receptor toward the membrane surface, which caused low nAChR cell-surface expression, and increased the intracellular nAChR pools. Moreover, Chol conditions muscle nAChR cell-surface diffusion and nAChR stability in confined raft domains.

Different results of the interaction between muscle nAChR and lipid domains were obtained in model systems. We observed that reconstituted Torpedo nAChR in symmetric model membranes with coexistence of liquid-ordered (lo) and liquid-disordered (ld) domains was distributed homogeneously, without preference for any domain. However, similar experiments with a synthetic peptide corresponding to the γM4 peptide showed a marked preference of this peptide for lo domains. Thus, although this transmembrane segment could give the nAChR the potentiality to localize in raft domains, it is not sufficient and other conditions must occur which influence nAChR partition profile. One of these mentioned conditions is membrane asymmetry. By increasing SM in the outer hemilayer, we observed an increment of the Torpedo nAChR in lo domains, and the same was observed when specific SM species instead of brain SM were used in symmetric models. Recently, by using coarse-grained molecular dynamics simulations of nAChR inserted in a ternary system of DPPC:Chol:PE or PC with PUFA, the authors concluded that nAChR partitioned in ld domains poor in Chol. The simulated membrane, despite having lo and ld domains, (a) did not have SM of any species, which is a critical lipid for raft domains in biological membranes, (b) used PUFA which are known to behave as nAChR inhibitors probably by competition with Chol for non-annular sites, as the authors observed in the study, and (c) was symmetric, a condition different to the natural asymmetry of biological membranes. Thus, this work emphasizes that it is not just the presence of an lo domain, but also its physicochemical characteristics and specific lipid components which condition nAChRs agglomeration.

With respect to neuronal nAChR, it was observed that α7 nAChR is associated with Chol-rich microdomains at somatic spine-rich regions of ciliary neurons and that the maintenance of these receptors within these domains is Chol-dependent. Furthermore, in PC-12 cells, a rat pheochromocytoma cell line, α7 nAChR location in raft domains is necessary to regulate cAMP signal through the nicotinic activation, signaling that was altered by Chol depletion. A similar relation between α7 nAChR location at raft domains and efficiently signaling, with a direct Chol influence, was also observed in CG neurons. Disruption of raft domains in the same CG neurons increased the mobility of α7 nAChRs in the synaptic space. Disruption of raft domains by removal of Chol and/or SM in rat primary hippocampal neurons slowed the kinetics of α7 nAChR desensitization through increasing the rate of recovery from desensitization and increased the agonist affinity and single-channel conductance. The authors observed the effects of raft domains disruption also on α3β2 nAChRs functionality. These results confirm that, as with muscle nAChR, neuronal nAChR functionality is modulated by its lipid microenvironment with the raft domains integrity a critical factor. On the contrary, α7 nAChR at non-neural tissues, in rat arterial endothelial (RAEC) and human venous endothelial (HUVEC), was found to occur in non-raft subcellular membrane fractions.

Conclusion

Alzheimer’s disease is a progressive neurodegenerative condition, the etiopathogenic mechanisms of which are not totally understood. Due to its multifactorial character, the development of new drugs and effective treatments is still a challenge. Here, we intended to focus only in the processes related to this disease that occur in the cell membrane, which allows to observe the multiple crosslinking between specific lipids and the membrane proteins involved in the amyloid process. In a dry human brain, half of its weight corresponds to lipids, molecules with great chemical diversity and complex dynamical heterogeneities. Thus, it is not surprising that through the years more and more biological functions are being related to them. Raft domains are implicated in several of the events involved in AD. Chol is a very important lipid at synaptic membranes and it is also a principal author in AD, together with other lipids such as GM1, SM or PA. It is not surprising that APP, Aβ, nAChR and G4-PRiMA all have Chol-recognition amino acid sequences. Although there are still some controversies, there is no doubt that APP processing, Aβ production and Aβ action are intimately related to raft domains, and that the cholinergic system function is highly conditioned by both raft domains and Aβ. A continuous crosstalk between amyloid processing and cholinergic signaling occurs at physiological and pathological conditions, and shifting from one condition to the other is triggered by an imbalance in Aβ synthesis, being Chol homeostasis intimately implicated (Figure 3). Currently, the only available treatment for AD is a group of drugs that inhibit ACE. A better understanding of Aβ-α7 nAChR interactions and of the implication of Chol in particular, and membrane heterogeneities in general, could allow for a deepening of the understanding of this neurodegenerative pathology and could help define new therapeutic strategies and potential novel molecular targets.

The World Health Organization (WHO) declared dementia as a public health priority (in Priority Medicines for Europe and the World “A Public Health Approach to Innovation” by Saloni Tanna). The number of people worldwide with this condition is in continuous growth: whereas in 2010 this number was estimated to be 35.6 million, it is expected to be near 115.4 million in 2050, in line with the view that this number nearly doubles every 20 years. AD is the most common form of dementia and, hence, it has become a major public health problem because of the continuous increase in the age of the population (in fact, in 2050 it is expected that 22% of the world population will be aged 60 and over). Thus, it is imperative to count with specific biomarkers for early stages of the disease, to improve detection and evaluation and, of course, with effective therapies. At present, the only treatment available is symptomatic: ACE inhibitors, like physostigmine, tacrine, donepezil, rivastigmine, and galantamine. Although new knowledge is continuously emerging, until now and as suggested in this work, there is no consensus among the different coexisting hypotheses around this subject, several of which are antagonistic. This fact clearly contributes to the current situation: there is not a single specific AD treatment commercially available. A great variety of molecular targets were proposed for AD treatment, a few of which were explained here (like β and γ-secretases, α7 nAChR and ACE), and plenty of studies have been conducted on them. Much effort has been invested in this area, but more is still required. Science is facing a huge challenge. Further studies that contribute to the description and explanation of the AD etiopathology will be crucial for a final consensus on AD. Multitarget-drug design is an interesting strategy as AD involves a large number of different molecules. And finally, it should not be forgotten that membrane lipids are not just a “sea” where proteins function but, as explained in detail above, they are necessary for the proper function of these proteins. Chol, GM1, SM, among others, are important lipids for AChR function, conformation and membrane stabilization, and also for Aβ processing and Aβ-membrane insertion. Thus, lipid membrane perturbation, and hence, raft domains alteration and membrane signal perturbation, directly impact in several hot points of AD etiopathology and, for this reason, they can also be considered as interesting molecular targets for AD.

Author Contributions

CF and SA contributed to the design, analysis, interpretation, and writing of the manuscript.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 443

  1. 1.

    Abad-Rodriguez J. Ledesma M. D. Craessaerts K. Perga S. Medina M. Delacourte A. (2004 ). Neuronal membrane cholesterol loss enhances amyloid peptide generation. J. Cell. Biol. 167 953–960.

    Not in our library10.1083/jcb.200404149

  2. 2.

    Addona G. H. Sandermann H. Kloczewiak M. A. (1998 ). Where does cholesterol act during activation of the nicotinic acetylcholine receptor? Biochim. Biophys. Acta 1370 299–309.

    Not in our library10.1016/s0005-2736(97)00280-0

  3. 3.

    Ahyayauch H. Raab M. Busto J. V. Andraka N. Arrondo J. L. Masserini M. (2012 ). Binding of β-amyloid (1-42) peptide to negatively charged phospholipid membranes in the liquid-ordered state: modeling and experimental studies. Biophys. J. 103 453–463.

    Not in our library10.1016/j.bpj.2012.06.043

  4. 4.

    Albuquerque E. X. Pereira E. F. R. Alkondon M. Rogers S. W. (2009 ). Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol. Rev. 89 73–120.

    Not in our library10.1152/physrev.00015.2008

  5. 5.

    Alptüzün V. Prinz M. Hörr V. Scheiber J. Radacki K. Fallarero A. (2010 ). Interaction of (benzylidene-hydrazono)-1,4-dihydropyridines with beta-amyloid, acetylcholine, and butyrylcholine esterases. Bioorg. Med. Chem. 218 2049–2059.

    Not in our library10.1016/j.bmc.2010.01.002

  6. 6.

    Alvarez A. Alarcón R. Opazo C. Campos E. O. Muñoz F. J. Calderón F. H. (1998 ). Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer’s fibrils. J. Neurosci. 18 3213–3223.

    Not in our library10.1523/jneurosci.18-09-03213.1998

  7. 7.

    Andreasen N. Sjögren M. Blennow K. (2003 ). CSF markers for Alzheimer’s disease: total tau, phospho-tau and Abeta42. World J. Biol. Psychiatry 4 147–155.

    Not in our library10.1080/15622970310029912

  8. 8.

    Andreasen T. J. McNamee M. G. (1980 ). Inhibition of ion permeability control properties of acetylcholine receptor from Torpedo californica by long-chain fatty acids. Biochemistry 19 4719–4726.

    Not in our library10.1021/bi00561a027

  9. 9.

    Annaert W. G. Levesque L. Craessaerts K. Dierinck I. Snellings G. Westaway D. (1999 ). Presenilin 1 controls gamma-secretase processing of amyloid precursor protein in pre-golgi compartments of hippocampal neurons. J. Cell. Biol. 147 277–294.

    Not in our library10.1083/jcb.147.2.277

  10. 10.

    Antollini S. S. Barrantes F. J. (1998 ). Disclosure of discrete sites for phospholipid and sterols at the protein-lipid interface in native acetylcholine receptor-rich membrane. Biochemistry 37 16653–16662.

    Not in our library10.1021/bi9808215

  11. 11.

    Antollini S. S. Barrantes F. J. (2002 ). Unique effects of different fatty acid species on the physical properties of the torpedo acetylcholine receptor membrane. J. Biol. Chem. 277 1249–1254.

    Not in our library10.1074/jbc.m106618200

  12. 12.

    Antollini S. S. Barrantes F. J. (2016 ). Fatty Acid Regulation of Voltage- and Ligand-Gated Ion Channel Function. Front. Physiol. 28:573.

    Not in our library10.3389/fphys.2016.00573

  13. 13.

    Antollini S. S. Soto M. A. Bonini de Romanelli I. Gutiérrez-Merino C. Sotomayor P. Barrantes F. J. (1996 ). Physical state of bulk and protein-associated lipid in nicotinic acetylcholine receptor-rich membrane studied by laurdan generalized polarization and fluorescence energy transfer. Biophys. J. 70 1275–1284.

    Not in our library10.1016/s0006-3495(96)79684-4

  14. 14.

    Antollini S. S. Xu Y. Jiang H. Barrantes F. J. (2005 ). Fluorescence and molecular dynamics studies of the acetylcholine receptor gammaM4 transmembrane peptide in reconstituted systems. Mol. Membr. Biol. 22 471–483.

    Not in our library10.1080/09687860500367915

  15. 15.

    Arbor S. C. Lafontaine M. Cumbay M. (2016 ). Amyloid-beta Alzheimer targets -protein processing, lipid rafts, and amyloid-beta pores. Yale J. Biol. Med. 89 5–21.

    Not in our library

  16. 16.

    Ariga T. Kobayashi K. Hasegawa A. Kiso M. Ishida H. Miyatake T. (2001 ). Characterization of high-affinity binding between gangliosides and amyloid beta-protein. Arch. Biochem. Biophys. 388 225–230.

    Not in our library10.1006/abbi.2001.2304

  17. 17.

    Arispe N. Pollard H. B. Rojas E. (1993a ). Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes. Proc. Natl. Acad. Sci. U.S.A. 90 10573–10577.

    Not in our library10.1073/pnas.90.22.10573

  18. 18.

    Arispe N. Rojas E. Pollard H. B. (1993b ). Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc. Natl. Acad. Sci. U.S.A. 90 567–571.

    Not in our library10.1073/pnas.90.2.567

  19. 19.

    Arora K. Alfulaij N. Higa J. K. Panee J. Nichols R. A. (2013 ). Impact of sustained exposure to β-amyloid on calcium homeostasis and neuronal integrity in model nerve cell system expressing α4β2 nicotinic acetylcholine receptors. J. Biol. Chem. 288 11175–11190.

    Not in our library10.1074/jbc.m113.453746

  20. 20.

    Ashley R. H. Harroun T. A. Hauss T. Breen K. C. Bradshaw J. P. (2006 ). Autoinsertion of soluble oligomers of Alzheimer’s Abeta(1-42) peptide into cholesterol-containing membranes is accompanied by relocation of the sterol towards the bilayer surface. BMC. Struct. Biol. 6:21.

    Not in our library10.1186/1472-6807-6-21

  21. 21.

    Askarova S. Yang X. Lee J. C. (2011 ). Impacts of membrane biophysics in Alzheimer’s Disease: from amyloid precursor protein processing to Aβ peptide-induced membrane changes. Int. J. Alzheimers Dis. 2011:134971.

    Not in our library10.4061/2011/134971

  22. 22.

    Atack J. R. Perry E. K. Bonham J. R. Perry R. H. Tomlinson B. E. Blessed G. (1983 ). Molecular forms of acetylcholinesterase in senile dementia of Alzheimer type: selective loss of the intermediate (10S) form. Neurosci. Lett. 40 199–204.

    Not in our library10.1016/0304-3940(83)90302-6

  23. 23.

    Auld D. S. Kornecook T. J. Bastianetto S. Quirion R. (2002 ). Alzheimer’s disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog. Neurobiol. 68 209–245.

    Not in our library10.1016/s0301-0082(02)00079-5

  24. 24.

    Avdulov N. A. Chochina S. V. Igbavboa U. Warden C. S. Vassiliev A. V. Wood W. G. (1997 ). Lipid binding to amyloid beta-peptide aggregates: preferential binding of cholesterol as compared with phosphatidylcholine and fatty acids. J. Neurochem. 69 1746–1752.

    Not in our library10.1046/j.1471-4159.1997.69041746.x

  25. 25.

    Baenziger J. E. Corringer P. J. (2011 ). 3D structure and allosteric modulation of the transmembrane domain of pentameric ligand-gated ion channels. Neuropharmacology 60 116–125.

    Not in our library10.1016/j.neuropharm.2010.08.007

  26. 26.

    Baenziger J. E. daCosta C. J. B. (2013 ). Molecular mechanisms of acetylcholine receptor-lipid interactions: from model membranes to human biology. Biophys. Rev. 5 1–9.

    Not in our library10.1007/s12551-012-0078-77

  27. 27.

    Baenziger J. E. Hénault C. M. Therien J. P. D. Sun J. (2015 ). Nicotinic acetylcholine receptor-lipid interactions: mechanistic insight and biological function. Biochim. Biophys. Acta Biomembr. 1848 1806–1817.

    Not in our library10.1016/j.bbamem.2015.03.010

  28. 28.

    Baenziger J. E. Morris M. Darsaut T. E. Ryan S. E. (2000 ). Effect of membrane lipid composition on the conformational equilibria of the Nicotinic acetylcholine receptor. J. Biol. Chem. 275 777–784.

    Not in our library10.1074/jbc.275.2.777

  29. 29.

    Baenziger J. E. Ryan S. E. Goodreid M. M. Vuong N. Q. Sturgeon R. M. Corrie J. B. (2008 ). Lipid composition alters drug action at the Nicotinic acetylcholine receptor. Mol. Pharmacol. 73 880–890.

    Not in our library10.1124/mol.107.039008

  30. 30.

    Bagatolli L. A. (2010 ). Microscopy imaging of membrane domains. Biochim. Biophys. Acta 1798:1285.

    Not in our library10.1016/j.bbamem.2010.05.023

  31. 31.

    Baier C. J. Barrantes F. J. (2007 ). Sphingolipids are necessary for nicotinic acetylcholine receptor export in the early secretory pathway. J. Neurochem. 101 1072–1084.

    Not in our library10.1111/j.1471-4159.2007.04561.x

  32. 32.

    Baier C. J. Fantini J. Barrantes F. J. (2011 ). Disclosure of cholesterol recognition motifs in transmembrane domains of the human nicotinic acetylcholine receptor. Sci. Rep. 1:69.

    Not in our library10.1038/srep00069

  33. 33.

    Baier C. J. Gallegos C. E. Levi V. Barrantes F. J. (2010 ). Cholesterol modulation of nicotinic acetylcholine receptor surface mobility. Eur. Biophys 39 213–227.

    Not in our library10.1007/s00249-009-0521-522

  34. 34.

    Banerjee C. Nyengaard J. R. Wevers A. de Vos R. A. Jansen Steur E. N. Lindstrom J. (2000 ). Cellular expression of alpha7 Nicotinic Acetylcholine receptor protein in the temporal cortex in Alzheimer’s and Parkinson’s disease - A stereological approach. Neurobiol. Dis. 7 666–672.

    Not in our library10.1006/nbdi.2000.0317

  35. 35.

    Barenholz Y. (2004 ). Sphingomyelin and cholesterol: from membrane biophysics and rafts to potential medical applications. Subcell. Biochem. 37 167–215.

    Not in our library10.1007/978-1-4757-5806-1_5

  36. 36.

    Barrantes F. J. (2002 ). Lipid matters: nicotinic acetylcholine receptor-lipid interactions. Mol. Membr. Biol. 219 277–284.

    Not in our library10.1080/09687680210166226

  37. 37.

    Barrantes F. J. (2007 ). Cholesterol effects on nicotinic acetylcholine receptor. Neurochem. 103 72–80.

    Not in our library10.1111/j.1471-4159.2007.04719.x

  38. 38.

    Barrantes F. J. (2010 ). Cholesterol effects on nicotinic acetylcholine receptor: cellular aspects. Subcell. Biochem. 51 467–487.

    Not in our library10.1007/978-90-481-8622-8_17

  39. 39.

    Barrantes F. J. (2015 ). Phylogenetic conservation of protein-lipid motifs in pentameric ligand-gated ion channels. Biochim. Biophys. Acta 1848 1796–1805.

    Not in our library10.1016/j.bbamem.2015.03.028

  40. 40.

    Barrantes F. J. Borroni V. Vallés S. (2010 ). Neuronal nicotinic acetylcholine receptor – cholesterol crosstalk in Alzheimer’s disease. FEBS Lett. 584 1856–1863.

    Not in our library10.1016/j.febslet.2009.11.036

  41. 41.

    Barrera N. P. Zhou M. Robinson C. V. (2013 ). The role of lipids in defining membrane protein interactions: insights from mass spectrometry. Trends. Cell. Biol. 23 1–8.

    Not in our library10.1016/j.tcb.2012.08.007

  42. 42.

    Barrett P. J. Song Y. Horn W. D. Van Hustedt E. J. Johanna M. Hadziselimovic A. (2012 ). The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science. 336 1168–1171.

    Not in our library10.1126/science.1219988

  43. 43.

    Bartolini M. Bertucci C. Cavrini V. Andrisano V. (2003 ). Beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem. Pharmacol. 65 407–416.

    Not in our library10.1016/s0006-2952(02)01514-9

  44. 44.

    Bartus R. T. Dean R. L. Beer B. Lippa A. S. (1982 ). The cholinergic hypothesis of geriatric memory dysfunction. Science 1217 408–414.

    Not in our library10.1126/science.7046051

  45. 45.

    Bazzi M. D. Nelsestuen G. L. (1996 ). Extensive segregation of acidic phospholipids in membranes induced by protein kinase C and related proteins. Biochemistry 32 7961–7969.

    Not in our library10.1021/bi00246a013

  46. 46.

    Beel A. J. Sakakura M. Barrett P. J. Sanders C. R. (2010 ). Direct binding of cholesterol to the amyloid precursor protein: an important interaction in lipid-Alzheimer’s disease relationships? Biochim. Biophys. Acta 1801 975–982.

    Not in our library10.1016/j.bbalip.2010.03.008

  47. 47.

    Behl C. Davis J. B. Lesley R. Schubert D. (1994 ). Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77 817–827.

    Not in our library10.1016/0092-8674(94)90131-7

  48. 48.

    Berg D. K. Conroy W. G. (2002 ). Nicotinic alpha 7 receptors: synaptic options and downstream signaling in neurons. J. Neurobiol. 53 512–523.

    Not in our library10.1002/neu.10116

  49. 49.

    Bermúdez V. Antollini S. S. Nievas G. A. F. Aveldaño M. I. Barrantes F. J. (2010 ). Partition profile of the nicotinic acetylcholine receptor in lipid domains upon reconstitution. J. Lipid Res. 51 2629–2641.

    Not in our library10.1194/jlr.m005132

  50. 50.

    Bieschke J. Zhang Q. Powers E. T. Lerner R. A. Kelly J. W. (2005 ). Oxidative metabolites accelerate Alzheimer’s amyloidogenesis by a two-step mechanism, eliminating the requirement for nucleation. Biochemistry 44 4977–4983.

    Not in our library10.1021/bi0501030

  51. 51.

    Bigl V. Woolf N. J. Butcher L. L. (1982 ). Cholinergic projections from the basal forebrain to frontal, parietal, temporal, occipital, and cingulate cortices: a combined fluorescent tracer and acetylcholinesterase analysis. Brain Res. Bull. 8 727–749.

    Not in our library10.1016/0361-9230(82)90101-0

  52. 52.

    Blanton M. P. Xie Y. Dangott L. J. Cohen J. B. (1999 ). The steroid promegestone is a noncompetitive antagonist of the Torpedo nicotinic acetylcholine receptor that interacts with the lipid-protein interface. Mol. Pharmacol. 55 269–278.

    Not in our library10.1124/mol.55.2.269

  53. 53.

    Bodovitz S. Klein W. L. (1996 ). Cholesterol Modulates alpha-Secretase Cleavage of Amyloid Precursor Protein. J. Biol. Chem. 271 4436–4440.

    Not in our library10.1074/jbc.271.8.4436

  54. 54.

    Bonini I. C. Antollini S. S. Gutiérrez-Merino C. Barrantes F. J. (2002 ). Sphingomyelin composition and physical asymmetries in native acetylcholine receptor-rich membranes. Eur. Biophys. J. 31 417–427.

    Not in our library10.1007/s00249-002-0230-236

  55. 55.

    Borroni V. Baier C. J. Lang T. Bonini I. White M. M. Garbus I. (2007 ). Cholesterol depletion activates rapid internalization of submicron-sized acetylcholine receptor domains at the cell membrane. Mol. Membr. Biol. 24 1–15.

    Not in our library10.1080/09687860600903387

  56. 56.

    Borroni V. Barrantes F. J. (2011 ). Cholesterol Modulates the Rate and Mechanism of Acetylcholine Receptor Internalization. J Biol Chem. 286 17122–17132.

    Not in our library10.1074/jbc.m110.211870

  57. 57.

    Bouzat C. Barrantes F. J. (1996 ). Modulation of muscle nicotinic acetylcholine receptors by the glucocorticoid hydrocortisone. Possible allosteric mechanism of channel blockade. J. Biol. Chem. 271 25835–25841.

    Not in our library10.1074/jbc.271.42.25835

  58. 58.

    Bouzat C. B. Lacorazza H. D. de Jiménez Bonino M. B. Barrantes F. J. (1993 ). Effect of chemical modification of extracellular histidyl residues on the channel properties of the nicotinic acetylcholine receptor. Pflugers. Arch. 423 365–371.

    Not in our library10.1007/bf00374929

  59. 59.

    Bowen D. M. Smith C. B. White P. Davison A. N. (1976 ). Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99 459–496.

    Not in our library10.1093/brain/99.3.459

  60. 60.

    Boyd-Kimball D. Castegna A. Sultana R. Poon H. F. Petroze R. Lynn B. C. (2005 ). Proteomic identification of proteins oxidized by Abeta(1-42) in synaptosomes: implications for Alzheimer’s disease. Brain Res. 1044 206–215.

    Not in our library10.1016/j.brainres.2005.02.086

  61. 61.

    Brannigan G. Hénin J. Law R. Eckenhoff R. Klein M. L. (2008 ). Embedded cholesterol in the nicotinic acetylcholine receptor. Proc. Natl. Acad. Sci. U.S.A. 105 14418–14423.

    Not in our library10.1073/pnas.0803029105

  62. 62.

    Brown D. A. (2006 ). Acetylcholine. Br. J. Pharmacol. 147(Suppl. 1), S120–S126.

    Not in our library10.1038/sj.bjp.0706474

  63. 63.

    Brown D. A. London E. (2000 ). Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J. Biol. Chem. 275 17221–17224.

    Not in our library10.1074/jbc.r000005200

  64. 64.

    Brusés J. L. Chauvet N. Rutishauser U. (2001 ). Membrane lipid rafts are necessary for the maintenance of the (alpha)7 nicotinic acetylcholine receptor in somatic spines of ciliary neurons. J. Neurosci. 21 504–512.

    Not in our library10.1523/jneurosci.21-02-00504.2001

  65. 65.

    Burke D. A. Heshmati P. Kholdebarin E. Levin E. D. (2014 ). Decreasing nicotinic receptor activity and the spatial learning impairment caused by the NMDA glutamate antagonist dizocilpine in rats. Eur. J. Pharmacol. 741 132–139.

    Not in our library10.1016/j.ejphar.2014.07.030

  66. 66.

    Burns M. Duff K. (2002 ). Cholesterol in Alzheimer’s disease and tauopathy. Ann. N. Y. Acad. Sci. 977 367–375.

    Not in our library10.1111/j.1749-6632.2002.tb04839.x

  67. 67.

    Butler D. H. McNamee M. G. (1993 ). FTIR analysis of nicotinic acetylcholine receptor secondary structure in reconstituted membranes. Biochim. Biophys. Acta 11150 17–24.

    Not in our library10.1016/0005-2736(93)90116-h

  68. 68.

    Butterfield D. A. Boyd-Kimball D. (2005 ). The critical role of methionine 35 in Alzheimer’s amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity. Biochim. Biophys. Acta 1703 149–156.

    Not in our library10.1016/j.bbapap.2004.10.014

  69. 69.

    Butterfield D. A. Swomley A. M. Sultana R. (2013 ). Amyloid β-Peptide (1–42)-induced oxidative stress in Alzheimer disease: importance in disease Pathogenesis and Progression. Antioxid. Redox. Signal. 19 823–835.

    Not in our library10.1089/ars.2012.5027

  70. 70.

    Campagna J. A. Fallon J. (2006 ). Lipid rafts are involved in C95 (4,8) agrin fragment-induced acetylcholine receptor clustering. Neuroscience 138 123–132.

    Not in our library10.1016/j.neuroscience.2005.11.019

  71. 71.

    Campanari M. L. García-Ayllón M. S. Belbin O. Galcerán J. Lleó A. Sáez-Valero J. (2014 ). Acetylcholinesterase modulates presenilin-1 levels and γ-secretase activity. J. Alzheimers Dis. 41 911–924.

    Not in our library10.3233/jad-140426

  72. 72.

    Cartaud A. Stetzkowski-Marden F. Maoui A. Cartaud J. (2011 ). Agrin triggers the clustering of raft-associated acetylcholine receptors through actin cytoskeleton reorganization. Biol. Cell. 103 287–301.

    Not in our library10.1042/bc20110018

  73. 73.

    Cascella R. Evangelisti E. Bigi A. Becatti M. Fiorillo C. Stefani M. (2017 ). Soluble oligomers require a ganglioside to trigger neuronal calcium overload. J. Alzheimers. Dis. 60 923–938.

    Not in our library10.3233/jad-170340

  74. 74.

    Cecchi C. Nichino D. Zampagni M. Bernacchioni C. Evangelisti E. Pensal A. (2009 ). A protective role for lipid raft cholesterol against amyloid-induced membrane damage in human neuroblastoma cells. Biochim. Biophys. Acta 1788 2204–2216.

    Not in our library10.1016/j.bbamem.2009.07.019

  75. 75.

    Champtiaux N. Gotti C. Cordero-Erausquin M. David D. J. Przybylski C. Léna C. (2003 ). Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J. Neurosci. 23 7820–7829.

    Not in our library10.1523/jneurosci.23-21-07820.2003

  76. 76.

    Chang T. Yamauchi Y. Hasan M. T. Chang C. (2017 ). Cellular cholesterol homeostasis and Alzheimer’s disease. J. Lipid. Res. 58 2239–2254.

    Not in our library10.1194/jlr.r075630

  77. 77.

    Changeux J. P. Edelstein S. J. (1998 ). Allosteric receptors after 30 years. Neuron 21 959–980.

    Not in our library10.1016/s0896-6273(00)80616-9

  78. 78.

    Cheignon C. Tomas M. Bonnefont-Rousselot D. Faller P. Hureau C. Collin F. (2018 ). Oxidative stress and the amyloid beta peptide in Alzheimer’s disease. Redox Biol. 14 450–464.

    Not in our library10.1016/j.redox.2017.10.014

  79. 79.

    Chernomordik L. V. Zimmerberg J. (1995 ). Bending membranes to the task: structural intermediates in bilayer fusion. Curr. Opin. Struct. Biol. 5 541–547.

    Not in our library10.1016/0959-440x(95)80041-7

  80. 80.

    Chochina S. V. Avdulov N. A. Igbavboa U. Cleary J. P. O’Hare E. O. Wood W. G. (2001 ). Amyloid beta-peptide1-40 increases neuronal membrane fluidity: role of cholesterol and brain region. J. Lipid Res. 42 1292–1297.

    Not in our library

  81. 81.

    Choo-Smith L. P. Garzon-Rodriguez W. Glabe C. G. Surewicz W. K. (1997 ). Acceleration of amyloid fibril formation by specific binding of Abeta-(1-40) peptide to ganglioside-containing membrane vesicles. J. Biol. Chem. 272 22987–22990.

    Not in our library10.1074/jbc.272.37.22987

  82. 82.

    Chyung J. H. Raper D. M. Selkoe D. J. (2005 ). Gamma-secretase exists on the plasma membrane as an intact complex that accepts substrates and effects intramembrane cleavage. J. Biol. Chem. 280 4383–4392.

    Not in our library10.1074/jbc.m409272200

  83. 83.

    Clarke P. B. (1992 ). The fall and rise of neuronal alpha-bungarotoxin binding proteins. Trends Pharmacol. Sci. 113 407–413.

    Not in our library10.1016/0165-6147(92)90125-p

  84. 84.

    Colón-Sáez J. O. Yakel J. L. (2011 ). The α7 nicotinic acetylcholine receptor function in hippocampal neurons is regulated by the lipid composition of the plasma membrane. J. Physiol. 589 3163–3174.

    Not in our library10.1113/jphysiol.2011.209494

  85. 85.

    Contestabile A. (2011 ). The history of the cholinergic hypothesis. Behav. Brain Res. 221 334–340.

    Not in our library10.1016/j.bbr.2009.12.044

  86. 86.

    Cooper S. T. Harkness P. C. Baker E. R. Millar N. S. (1999 ). Up-regulation of cell-surface alpha4beta2 neuronal Nicotinic receptors by lower temperature and expression of chimeric subunits. J. Biol. Chem. 274 27145–27152.

    Not in our library10.1074/jbc.274.38.27145

  87. 87.

    Corbin J. Wang H. H. Blanton M. P. (1998 ). Identifying the cholesterol binding domain in the nicotinic acetylcholine receptor with [125I] azido-cholesterol. Biochim. Biophys. Acta 1414 65–74.

    Not in our library10.1016/s0005-2736(98)00153-9

  88. 88.

    Cordy J. M. Hooper N. M. Turner A. J. (2006 ). The involvement of lipid rafts in Alzheimer’s disease. Mol. Membr. Biol. 23 111–122.

    Not in our library10.1080/09687860500496417

  89. 89.

    Counts S. E. He B. Che S. Ikonomovic M. D. DeKosky S. T. Ginsberg S. D. (2007 ). Alpha7 nicotinic receptor up-regulation in cholinergic basal forebrain neurons in Alzheimer disease. Arch. Neurol. 64 1771–1776.

    Not in our library10.1001/archneur.64.12.1771

  90. 90.

    Court J. A. Piggott M. A. Lloyd S. Cookson N. Ballard C. G. McKeith I. G. (2000 ). Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson’s disease and Alzheimer’s disease and in relation to neuroleptic medication. Neuroscience 98 79–87.

    Not in our library10.1016/s0306-4522(00)00071-3

  91. 91.

    Coyle J. T. Price D. L. DeLong M. R. (1983 ). Alzheimer’s disease: a disorder of cortical cholinergic innervation. Science 219 1184–1190.

    Not in our library10.1126/science.6338589

  92. 92.

    Criado M. Eibl H. Barrantes F. J. (1984 ). Functional properties of the acetylcholine receptor incorporated in model lipid membranes. Differential effects of chain length and head group of phospholipids on receptor affinity states and receptor-mediated ion translocation. J. Biol. Chem. 259 9188–9198.

    Not in our library

  93. 93.

    Criado M. Vaz W. L. Barrantes F. J. Jovin T. M. (1982 ). Translational diffusion of acetylcholine receptor (monomeric and dimeric forms) of Torpedo marmorata reconstituted into phospholipid bilayers studied by fluorescence recovery after photobleaching. Biochemistry 21 5750–5755.

    Not in our library10.1021/bi00266a004

  94. 94.

    Cutler R. G. Kelly J. Storie K. Pedersen W. A. Tammara A. Hatanpaa K. (2004 ). Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease. Proc. Natl. Acad. Sci. U.S.A. 101 2070–2075.

    Not in our library10.1073/pnas.0305799101

  95. 95.

    daCosta C. J. Ogrel A. A. McCardy E. A. Blanton M. P. Baenziger J. E. (2002 ). Lipid-protein interactions at the nicotinic acetylcholine receptor. A functional coupling between Nicotinic receptors and Phosphatidic acid-containing lipid bilayers. J. Biol. Chem. 277 201–208.

    Not in our library10.1074/jbc.m108341200

  96. 96.

    daCosta C. J. Wagg I. D. McKay M. E. Baenziger J. E. (2004 ). Phosphatidic acid and phosphatidylserine have distinct structural and functional interactions with the nicotinic acetylcholine receptor. J. Biol. Chem. 279 14967–14974.

    Not in our library10.1074/jbc.m310037200

  97. 97.

    daCosta C. J. B. Baenziger J. E. (2009 ). A lipid-dependent uncoupled conformation of the acetylcholine receptor. J. Biol. Chem. 284 17819–17825.

    Not in our library10.1074/jbc.m900030200

  98. 98.

    Dajas-Bailador F. Wonnacott S. (2004 ). Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends. Pharmacol. Sci. 25 317–324.

    Not in our library10.1016/s0165-6147(04)00118-x

  99. 99.
    Regulation of transbilayer plasma membrane phospholipid asymmetry · 2003
    Not checked
  100. 100.

    D’Andrea M. R. Nagele R. G. (2006 ). Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer’s disease pyramidal neurons. Curr. Pharm. Des. 12 677–684.

    Not in our library10.2174/138161206775474224

  101. 101.

    Daugherty B. L. Green S. A. (2001 ). Endosomal sorting of amyloid precursor protein-P-selectin chimeras influences secretase processing. Traffic 2 908–916.

    Not in our library10.1034/j.1600-0854.2001.21206.x

  102. 102.

    Davies P. Maloney A. J. (1976 ). Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 2:1403

    Not in our library10.1016/s0140-6736(76)91936-x

  103. 103.

    de Almeida R. F. Loura L. M. Prieto M. Watts A. Fedorov A. Barrantes F. J. (2004 ). Cholesterol modulates the organization of the gammaM4 transmembrane domain of the muscle nicotinic acetylcholine receptor. Biophys. J. 86 2261–2272.

    Not in our library10.1016/s0006-3495(04)74284-74288

  104. 104.

    Deutsch S. I. Burket J. A. Benson A. D. (2014 ). Targeting the α7 nicotinic acetylcholine receptor to prevent progressive dementia and improve cognition in adults with Down’s syndrome. Prog. Neuropsychopharmacol. Biol. Psychiatry 254 131–139.

    Not in our library10.1016/j.pnpbp.2014.05.011

  105. 105.

    Deutsch S. I. Burket J. A. Benson A. D. Urbano M. R. (2016 ). The 15q13.3 deletion syndrome: Deficient α(7)-containing nicotinic acetylcholine receptor-mediated neurotransmission in the pathogenesis of neurodevelopmental disorders. Prog. Neuropsychopharmacol. Biol Psychiatry 64 09–17.

    Not in our library10.1016/j.pnpbp.2015.08.001

  106. 106.

    Di Scala C. Baier C. J. Evans L. S. Williamson P. T. F. Fantini J. Barrantes F. J. (2017 ). Relevance of CARC and CRAC Cholesterol-Recognition Motifs in the Nicotinic Acetylcholine Receptor and Other Membrane-Bound Receptors. Curr. Top. Membr. 80 3–23.

    Not in our library10.1016/bs.ctm.2017.05.001

  107. 107.

    Di Scala C. Chahinian H. Yahi N. Garmy N. Fantini J. (2014 ). Interaction of Alzheimer’s β-amyloid peptides with cholesterol: mechanistic insights into amyloid pore formation. Biochemistry 53 4489–4502.

    Not in our library10.1021/bi500373k

  108. 108.
    Common molecular mechanism of amyloid pore formation by Alzheimer’s β-amyloid peptide and α-synuclein · 2016
    No notice
  109. 109.

    Di Scala C. Yahi N. Lelièvre C. Garmy N. Chahinian H. Fantini J. (2013 ). Biochemical identification of a linear cholesterol-binding domain within Alzheimer’s β amyloid peptide. ACS Chem. Neurosci. 4 509–517.

    Not in our library10.1021/cn300203a

  110. 110.

    Dickey A. N. Faller R. (2008 ). Behavioral differences between Phosphatidic acid and Phosphatidylcholine in the Presence of the Nicotinic Acetylcholine receptor. Biophys. J. 95 5637–5647.

    Not in our library10.1529/biophysj.108.136895

  111. 111.
    The interaction between amyloid-β peptides and anionic lipid membranes containing cholesterol and melatonin. · 2014
    Not checked
  112. 112.

    Dineley K. T. (2007 ). Beta-amyloid peptide–nicotinic acetylcholine receptor interaction: the two faces of health and disease. Front. Biosci. 12:5030–5038.

    Not in our library10.2741/2445

  113. 113.

    Dineley K. T. Bell K. A. Bui D. Sweatt J. D. (2002 ). Beta -Amyloid peptide activates alpha 7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J. Biol. Chem. 277 25056–25061.

    Not in our library10.1074/jbc.m200066200

  114. 114.

    Dineley K. T. Westerman M. Bui D. Bell K. Ashe K. H. Sweatt J. D. (2001 ). Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: in vitro and in vivo mechanisms related to Alzheimer’s disease. J. Neurosci. 21 4125–4133.

    Not in our library10.1523/jneurosci.21-12-04125.2001

  115. 115.

    Dougherty J. J. Wu J. Nichols R. A. (2003 ). Beta-amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. J. Neurosci. 23 6740–6747.

    Not in our library10.1523/jneurosci.23-17-06740.2003

  116. 116.

    Dreger M. Krauss M. Herrmann A. Hucho F. (1997 ). Interactions of the Nicotinic acetylcholine receptor Transmembrane segments with the Lipid Bilayer in Native receptor-rich membranes. Biochemistry 36 839–847.

    Not in our library10.1021/bi960666z

  117. 117.

    Dukhinova M. Veremeyko T. Yung A. W. Y. Kuznetsova I. S. Lau T. Y. B. Kopeikina E. (2019 ). Fresh evidence for major brain gangliosides as a target for the treatment of Alzheimer’s disease. Neurobiol. Aging 77 128–143.

    Not in our library10.1016/j.neurobiolaging.2019.01.020

  118. 118.

    Dvir H. Silman I. Harel M. Rosenberry T. L. Sussman J. L. (2010 ). Acetylcholinesterase: from 3D structure to function. Chem. Biol. Interact. 187 10–22.

    Not in our library10.1016/j.cbi.2010.01.042

  119. 119.

    Dziewczapolski G. Glogowski C. M. Masliah E. Heinemann S. F. (2009 ). Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer’s disease. J. Neurosci. 29 8805–8815.

    Not in our library10.1523/jneurosci.6159-08.2009

  120. 120.

    Eckert G. P. Kirsch C. Leutz S. Wood W. G. Müller W. E. (2003 ). Cholesterol Modulates Amyloid Beta-peptide’s Membrane Interactions. Pharmacopsychiatry 36(Suppl. 2), S136–S143.

    Not in our library10.1055/s-2003-43059

  121. 121.

    Ehehalt R. Keller P. Haass C. Thiele C. Simons K. (2003 ). Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell. Biol. 160 113–123.

    Not in our library10.1083/jcb.200207113

  122. 122.

    Ellena J. F. Blazing M. A. McNamee M. G. (1983 ). Lipid-protein interactions in reconstituted membranes containing Acetylcholine receptor. Biochemistry 22 5523–5535.

    Not in our library10.1021/bi00293a012

  123. 123.

    Engel M. F. Khemtémourian L. Kleijer C. C. Meeldijk H. J. Jacobs J. Verkleij A. J. (2008 ). Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane. Proc. Natl. Acad. Sci. U.S.A. 105 6033–6038.

    Not in our library10.1073/pnas.0708354105

  124. 124.

    Engelman D. M. (2005 ). Membranes are more mosaic than fluid. Nature 438 578–580.

    Not in our library10.1038/nature04394

  125. 125.

    Epand R. F. Kraayenhof R. Sterk G. J. Wong Fong Sang H. W. Epand R. M. (1996 ). Fluorescent probes of membrane surface properties. Biochim Biophys Acta 1284 191–195.

    Not in our library10.1016/s0005-2736(96)00124-1

  126. 126.

    Fabelo N. Martín V. Marín R. Moreno D. Ferrer I. Díaz M. (2014 ). Altered lipid composition in cortical lipid rafts occurs at early stages of sporadic Alzheimer’s disease and facilitates APP/BACE1 interactions. Neurobiol. Aging 35 1801–1812.

    Not in our library10.1016/j.neurobiolaging.2014.02.005

  127. 127.
    How cholesterol interacts with membrane proteins: an exploration of cholesterol-binding sites including CRAC, CARC, and tilted domains · 2013
    No notice
  128. 128.

    Fantini J. Di Scala C. Evans L. S. Williamson P. T. F. Barrantes F. J. (2016 ). Open a mirror code for protein- cholesterol interactions in the two leaflets of biological membranes. Sci. Rep. 26:21907.

    Not in our library10.1038/srep21907

  129. 129.

    Fantini J. Di Scala C. Yahi N. Troadec J. D. Sadelli K. Chahinian H. (2014 ). Bxarotene blocks calcium-permeable ion channels formed by neurotoxic Alzheimer’s β-amyloid peptides. ACS Chem. Neurosci. 5 216–224.

    Not in our library10.1021/cn400183w

  130. 130.

    Farhat S. M. Ahmed T. (2017 ). Neuroprotective and Neurotoxic implications of α7 Nicotinic Acetylcholine receptor and Aβ Interaction: Therapeutic options in Alzheimer’s Disease. Curr. Drug. Targets 18 1537–1544.

    Not in our library10.2174/1389450117666161005145143

  131. 131.

    Fassbender K. Masters C. Beyreuther K. (2001 ). Alzheimer’s disease: molecular concepts and therapeutic targets. Naturwissenschaften 88 261–267.

    Not in our library10.1007/s001140100237

  132. 132.
    Antioxidant Therapies for Alzheimer's Disease · 2012
    No notice
  133. 133.

    Fernandes C. C. Berg D. K. Gómez-Varela D. (2010 ). Lateral mobility of nicotinic acetylcholine receptors on neurons is determined by receptor composition, local domain, and cell type. J. Neurosci. 30 8841–8851.

    Not in our library10.1523/jneurosci.6236-09.2010

  134. 134.

    Fernández Nievas G. A. Barrantes F. J. Antollini S. S. (2007 ). Conformation-sensitive steroid and fatty acid sites in the transmembrane domain of the nicotinic acetylcholine receptor. Biochemistry 46 3503–3512.

    Not in our library10.1021/bi061388z

  135. 135.

    Fernández Nievas G. A. Barrantes F. J. Antollini S. S. (2008 ). Modulation of nicotinic acetylcholine receptor conformational state by free fatty acids and steroids. J. Biol. Chem. 283 21478–21486.

    Not in our library10.1074/jbc.m800345200

  136. 136.

    Fernández-Ballester G. Castresana J. Fernandez A. M. Arrondo J. L. Ferragut J. A. Gonzalez-Ros J. M. (1994 ). Role of cholesterol as a structural and functional effector of the nicotinic acetylcholine receptor. Biochem. Soc. Trans. 122 776–780.

    Not in our library10.1042/bst0220776

  137. 137.

    Fishman E. B. Siek G. C. MacCallum R. D. Bird E. D. Volicer L. Marquis J. K. (1986 ). Distribution of the molecular forms of acetylcholinesterase in human brain: alterations in dementia of the Alzheimer type. Ann. Neurol. 119 246–252.

    Not in our library10.1002/ana.410190305

  138. 138.

    Fong T. M. McNamee M. G. (1986 ). Correlation between acetylcholine receptor function and structural properties of membranes. Biochemistry 25 830–840.

    Not in our library10.1021/bi00352a015

  139. 139.

    Fonseca A. C. Moreira P. I. Oliveira C. R. Cardoso S. M. Pinton P. Pereira C. F. (2015 ). Amyloid-Beta disrupts calcium and redox homeostasis in brain endothelial cells. Mol. Neurobiol 51 610–622.

    Not in our library10.1007/s12035-014-8740-8747

  140. 140.

    Frears E. R. Stephens D. J. Walters C. E. Davies H. Austen B. M. (1999 ). The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport 10 1699–1705.

    Not in our library10.1097/00001756-199906030-00014

  141. 141.

    Fucile S. (2004 ). Ca2+ permeability of nicotinic acetylcholine receptors. Cell. Calcium 35 1–8.

    Not in our library10.1016/j.ceca.2003.08.006

  142. 142.

    Fukaya T. Gondaira T. Kashiyae Y. Kotani S. Ishikura Y. Fujikawa S. (2007 ). Arachidonic acid preserves hippocampal neuron membrane fluidity in senescent rats. Neurobiol. Aging 28 1179–1186.

    Not in our library10.1016/j.neurobiolaging.2006.05.023

  143. 143.

    Fukunaga S. Ueno H. Yamaguchi T. Yano Y. Hoshino M. Matsuzaki K. (2012 ). GM1 cluster mediates formation of toxic Aβ fibrils by providing hydrophobic environments. Biochemistry 51 8125–8131.

    Not in our library10.1021/bi300839u

  144. 144.

    Garbus I. Bouzat C. Barrantes F. J. (2001 ). Steroids differentially inhibit the nicotinic acetylcholine receptor. Neuroreport 12 227–231.

    Not in our library10.1097/00001756-200102120-00010

  145. 145.

    Garbus I. Roccamo A. M. Barrantes F. J. (2002 ). Identification of threonine 422 in transmembrane domain alpha M4 of the nicotinic acetylcholine receptor as a possible site of interaction with hydrocortisone. Neuropharmacology 43 65–73.

    Not in our library10.1016/s0028-3908(02)00068-0

  146. 146.

    García-Ayllón M. Campanari M. Montenegro M. Cuchillo-ibáñez I. Belbin O. Lleó A. (2014 ). Neurobiology of aging Presenilin-1 influences processing of the acetylcholinesterase membrane anchor PRiMA. Neurobiol. Aging 35 1526–1536.

    Not in our library10.1016/j.neurobiolaging.2014.01.147

  147. 147.

    Geula C. Mesulam M. (1989 ). Special properties of cholinesterases in the cerebral cortex of Alzheimer’s disease. Brain Res. 498 185–189.

    Not in our library10.1016/0006-8993(89)90419-8

  148. 148.

    Ghoneim M. M. Mewaldt S. P. (1977 ). Studies on human memory: the interactions of diazepam, scopolamine, and physostigmine. Psychopharmacology 52 1–6.

    Not in our library10.1007/bf00426592

  149. 149.

    Ghribi O. Larsen B. Schrag M. Herman M. M. (2006 ). High cholesterol content in neurons increases BACE, β -amyloid, and phosphorylated tau levels in rabbit hippocampus. Exp. Neurol. 200 460–467.

    Not in our library10.1016/j.expneurol.2006.03.019

  150. 150.

    Gilbert R. J. (2016 ). Protein-lipid interactions and non-lamellar lipidic structures in membrane pore formation and membrane fusion. Biochim. Biophys. Acta 1858 487–499.

    Not in our library10.1016/j.bbamem.2015.11.026

  151. 151.

    Gilbert R. J. Dalla Serra M. Froelich C. J. Wallace M. I. Anderluh G. (2014 ). Membrane pore formation at protein-lipid interfaces. Trends Biochem. Sci. 39 510–516.

    Not in our library10.1016/j.tibs.2014.09.002

  152. 152.

    Giniatullin R. Nistri A. Yakel J. L. (2005 ). Desensitization of nicotinic ACh receptors: shaping cholinergic signaling. Trends. Neurosci. 28 371–378.

    Not in our library10.1016/j.tins.2005.04.009

  153. 153.

    Gong J. S. Sawamura N. Zou K. Sakai J. Yanagisawa K. Michikawa M. (2002 ). Amyloid beta-protein affects cholesterol metabolism in cultured neurons: implications for pivotal role of cholesterol in the amyloid cascade. Neurosci. Res. 70 438–446.

    Not in our library10.1002/jnr.10347

  154. 154.

    Goñi F. M. (2014 ). The basic structure and dynamics of cell membranes?: an update of the Singer - Nicolson model. Biochim. Biophys. Acta 1838 1467–1476.

    Not in our library10.1016/j.bbamem.2014.01.006

  155. 155.

    Gotti C. Clementi F. Fornari A. Gaimarri A. Guiducci S. Manfredi I. (2009 ). Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem. Pharmacol. 78 703–711.

    Not in our library10.1016/j.bcp.2009.05.024

  156. 156.

    Gotti C. Moretti M. Gaimarri A. Zanardi A. Clementi F. Zoli M. (2007 ). Heterogeneity and complexity of native brain nicotinic receptors. Biochem. Pharmacol. 74 1102–1111.

    Not in our library10.1016/j.bcp.2007.05.023

  157. 157.

    Gotti C. Riganti L. Vailati S. Clementi F. (2006b ). Brain neuronal nicotinic receptors as new targets for drug discovery. Curr. Pharm. Des. 12 407–428.

    Not in our library10.2174/138161206775474486

  158. 158.

    Gotti C. Zoli M. Clementi F. (2006a ). Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol. Sci. 27 482–491.

    Not in our library10.1016/j.tips.2006.07.004

  159. 159.

    Götz J. Schild A. Hoerndli F. Pennanen L. (2004 ). Amyloid-induced neurofibrillary tangle formation in Alzheimer’s disease: insight from transgenic mouse and tissue-culture models. Int. J. Dev. Neurosci. 22 453–465.

    Not in our library10.1016/j.ijdevneu.2004.07.013

  160. 160.

    Graham A. J. Martin-Ruiz C. M. Teaktong T. Ray M. A. Court J. A. (2002 ). Human brain nicotinic receptors, their distribution and participation in neuropsychiatric disorders. Curr. Drug. Targets CNS Neurol. Disord. 4 387–397.

    Not in our library10.2174/1568007023339283

  161. 161.
    Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer β-amyloid peptides · 1999
    Not checked
  162. 162.

    Grimm M. O. Grimm H. S. Hartmann T. (2007 ). Amyloid beta as a regulator of lipid homeostasis. Trends. Mol. Med. 13 337–344.

    Not in our library10.1016/j.molmed.2007.06.004

  163. 163.

    Grimm M. O. Grimm H. S. Pätzold A. J. Zinser E. G. Halonen R. Duering M. (2005 ). Regulation of cholesterol and sphingomyelin metabolism by amyloid- β and presenilin. Nat. Cell. Biol. 7 1118–1123.

    Not in our library10.1038/ncb1313

  164. 164.

    Grisaru D. Sternfeld M. Eldor A. Glick D. Soreq H. (1999 ). Structural roles of acetylcholinesterase variants in biology and pathology. Eur. J. Biochem. 264 672–686.

    Not in our library10.1046/j.1432-1327.1999.00693.x

  165. 165.

    Gu L. Guo Z. (2013 ). Alzheimer’s Aβ42 and Aβ40 peptides form interlaced amyloid fibrils. J. Neurochem. 126 305–311.

    Not in our library10.1111/jnc.12202

  166. 166.

    Guillem K. Bloem B. Poorthuis R. B. Loos M. Smit A. B. Maskos U. (2011 ). Nicotinic acetylcholine receptor β2 subunits in the medial prefrontal cortex control attention. Science 333 888–891.

    Not in our library10.1126/science.1207079

  167. 167.

    Gylys K. H. Fein J. A. Yang F. Miller C. A. Cole G. M. (2007 ). Increased cholesterol in Abeta-positive nerve terminals from Alzheimer’s disease cortex. Neurobiol. Aging 28 8–17.

    Not in our library10.1016/j.neurobiolaging.2005.10.018

  168. 168.

    Gyure K. A. Durham R. Stewart W. F. Smialek J. E. Troncoso J. C. (2001 ). Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch. Pathol. Lab. Med. 125 489–492.

    Not in our library10.5858/2001-125-0489-iaapdo

  169. 169.

    Haass C. (1996 ). The molecular significance of amyloid beta-peptide for Alzheimer’s disease. Eur. Arch. Psychiatry. Clin. Neurosci. 246 118–123.

    Not in our library10.1007/bf02189111

  170. 170.

    Haass C. Kaether C. Thinakaran G. Sisodia S. (2012 ). Trafficking and Proteolytic Processing of APP. Cold. Spring. Harb. Perspect. Med. 2 1–25.

    Not in our library10.1101/cshperspect.a006270

  171. 171.

    Hamouda A. K. Chiara D. C. Sauls D. Cohen J. B. Blanton M. P. (2006 ). Cholesterol interacts with transmembrane alpha-helices M1, M3, and M4 of the Torpedo nicotinic acetylcholine receptor: photolabeling studies using [3H]Azicholesterol. Biochemistry 45 976–986.

    Not in our library10.1021/bi051978h

  172. 172.

    Hampel H. Mesulam M. M. Cuello A. C. Farlow M. R. Giacobini E. Grossberg G. T. (2018 ). The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain 141 1917–1933.

    Not in our library10.1093/brain/awy132

  173. 173.

    Hardy J. A. Allsop D. (1991 ). Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends. Pharmacol. 12 383–388.

    Not in our library10.1016/0165-6147(91)90609-v

  174. 174.

    Hardy J. A. Higgins G. A. (1992 ). Alzheimer’s Disease?: the amyloid cascade hypothesis. Science 256 184–185.

    Not in our library10.1126/science.1566067

  175. 175.

    Harris J. R. (2008 ). Cholesterol binding to amyloid-b fibrils: a TEM study. Micron 39 1192–1196.

    Not in our library10.1016/j.micron.2008.05.001

  176. 176.

    Hellström-Lindahl E. Court J. Keverne J. Svedberg M. Lee M. Marutle A. (2004a ). Nicotine reduces A beta in the brain and cerebral vessels of APPsw mice. Eur. J. Neurosci. 19 2703–2710.

    Not in our library10.1111/j.0953-816x.2004.03377.x

  177. 177.

    Hellström-Lindahl E. Mousavi M. Ravid R. Nordberg A. (2004b ). Reduced levels of Abeta 40 and Abeta 42 in brains of smoking controls and Alzheimer’s patients. Neurobiol. Dis. 15 351–360.

    Not in our library10.1016/j.nbd.2003.11.024

  178. 178.

    Hellström-Lindahl E. Mousavi M. Zhang X. Ravid R. Nordberg A. (1999 ). Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. Brain Res. Mol. Brain. Res. 661 94–103.

    Not in our library10.1016/s0169-328x(99)00030-3

  179. 179.

    Hénault C. M. Sun J. Therien J. P. daCosta C. J. Carswell C. L. Labriola J. M. (2015 ). The role of the M4 lipid-sensor in the folding, trafficking, and allosteric modulation of nicotinic acetylcholine receptors. Neuropharmacology 296 157–168.

    Not in our library10.1016/j.neuropharm.2014.11.011

  180. 180.

    Henderson Z. Boros A. Janzso G. Westwood A. J. Monyer H. Halasy K. (2005 ). Somato-dendritic nicotinic receptor responses recorded in vitro from the medial septal diagonal band complex of the rodent. J. Physiol. Lond. 562 165–182.

    Not in our library10.1113/jphysiol.2004.070300

  181. 181.

    Henderson Z. Matto N. John D. Nalivaeva N. N. Turner A. J. (2010 ). Co-localization of PRiMA with acetylcholinesterase in cholinergic neurons of rat brain: an immunocytochemical study. Brain Res. 1344 34–42.

    Not in our library10.1016/j.brainres.2010.05.022

  182. 182.

    Herrup K. (2015 ). The case for rejecting the amyloid cascade hypothesis. Nat. Neurosci. 18 794–799.

    Not in our library10.1038/nn.4017

  183. 183.

    Hertel C. Terzi E. Hauser N. Jakob-Rotne R. Seelig J. Kemp J. A. (1997 ). Inhibition of the electrostatic interaction between beta-amyloid peptide and membranes prevents beta-amyloid-induced toxicity. Proc. Natl. Acad. Sci. U.S.A. 94 9412–9416.

    Not in our library10.1073/pnas.94.17.9412

  184. 184.

    Hicks D. A. John D. Makova N. Z. Henderson Z. Nalivaeva N. N. Turner A. J. (2011 ). Membrane targeting, shedding and protein interactions of brain acetylcholinesterase. J. Neurochem. 116 742–746.

    Not in our library10.1111/j.1471-4159.2010.07032.x

  185. 185.

    Hicks D. A. Makova N. Z. Gough M. Parkin E. T. Nalivaeva N. N. Turner A. J. (2013b ). The amyloid precursor protein represses expression of acetylcholinesterase in neuronal cell lines. J. Biol. Chem. 288 26039–26051.

    Not in our library10.1074/jbc.m113.461269

  186. 186.

    Hicks D. A. Makova N. Z. Nalivaeva N. N. Turner A. J. (2013a ). Chemico-Biological Interactions Characterisation of acetylcholinesterase release from neuronal cells. Chem. Biol. Interact. 203 302–308.

    Not in our library10.1016/j.cbi.2012.09.019

  187. 187.

    Hicks D. A. Nalivaeva N. N. Turner A. J. (2012 ). Lipid rafts and Alzheimer’s disease?: protein-lipid interactions and perturbation of signaling. Front. Physiol. 3:189.

    Not in our library10.3389/fphys.2012.00189

  188. 188.

    Hong S. Ostaszewski B. L. Yang T. Malley T. T. O. Jin M. Yanagisawa K. (2014 ). Soluble Aβ oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes. Neuron. 82 308–319.

    Not in our library10.1016/j.neuron.2014.02.027

  189. 189.

    Hou X. Richardson S. J. Aguilar M. I. Small D. H. (2005 ). Binding of amyloidogenic transthyretin to the plasma membrane alters membrane fluidity and induces neurotoxicity. Biochemistry 44 11618–11627.

    Not in our library10.1021/bi050700m

  190. 190.

    Huse J. T. Pijak D. S. Leslie G. J. Lee V. M. Doms R. W. (2000 ). Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer’s disease beta-secretase. J. Biol. Chem. 275 33729–33737.

    Not in our library10.1074/jbc.m004175200

  191. 191.

    Igbavboa U. Avdulov N. A. Schroeder F. Wood W. G. (1996 ). Increasing age alters transbilayer fluidity and cholesterol asymmetry in synaptic plasma membranes of mice. J. Neurochem. 66 1717–1725.

    Not in our library10.1046/j.1471-4159.1996.66041717.x

  192. 192.

    Ikonomovic M. D. Wecker L. Abrahamson E. E. Wuu J. Counts S. E. Ginsberg S. D. (2009 ). Cortical alpha7 nicotinic acetylcholine receptor and beta-amyloid levels in early Alzheimer disease. Arch. Neurol. 66 646–651.

    Not in our library10.1001/archneurol.2009.46

  193. 193.

    Inestrosa N. C. Alvarez A. Calderón F. (1996 ). Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid beta-peptide into Alzheimer’s filaments. Mol. Psychiatry 1 359–361.

    Not in our library

  194. 194.

    Irvine G. B. El-agnaf O. M. Shankar G. M. Walsh D. M. (2008 ). Protein aggregation in the brain: the molecular basis for Alzheimer’s and Parkinson’ s diseases. Mol. Med. 14 451–464.

    Not in our library10.2119/2007-00100

  195. 195.

    Iwatsubo T. Odaka A. Suzuki N. Mizusawa H. Nukina N. Ihara Y. (1994 ). Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13 45–53.

    Not in our library10.1016/0896-6273(94)90458-8

  196. 196.

    Jarrett J. T. Berger E. P. Lansbury P. T. Jr. (1993 ). The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer’s disease. Biochemistry 32 4693–4697.

    Not in our library10.1021/bi00069a001

  197. 197.

    Jha A. Cadugan D. J. Purohit P. Auerbach A. (2007 ). Acetylcholine receptor gating at extracellular transmembrane domain interface: the cys-loop and M2-M3 linker. J. Gen. Physiol. 130 547–558.

    Not in our library10.1085/jgp.200709856

  198. 198.

    Ji S. R. Wu Y. Sui S. F. (2002 ). Cholesterol is an important factor affecting the membrane insertion of beta-amyloid peptide (A beta 1-40), which may potentially inhibit the fibril formation. J. Biol. Chem. 277 6273–6279.

    Not in our library10.1074/jbc.m104146200

  199. 199.

    Jin Y. Tsuchiya A. Kanno T. Nishizaki T. (2015 ). Biochemical and biophysical research communications Amyloid- b peptide increases cell surface localization of a7 ACh receptor to protect neurons from amyloid b -induced damage. Biochem. Biophys. Res. Commun. 468 157–160.

    Not in our library10.1016/j.bbrc.2015.10.141

  200. 200.

    Jones I. W. Westmacott A. Chan E. Jones R. W. Dineley K. O’Neill M. J. (2006 ). Alpha7 nicotinic acetylcholine receptor expression in Alzheimer’s disease: receptor densities in brain regions of the APP(SWE) mouse model and in human peripheral blood lymphocytes. J. Mol. Neurosci. 30 83–84.

    Not in our library10.1385/jmn:30:1:83

  201. 201.

    Jones O. T. McNamee M. G. (1988 ). Annular and nonannular binding sites for cholesterol associated with the nicotinic acetylcholine receptor. Biochemistry 127 2364–2374.

    Not in our library10.1021/bi00407a018

  202. 202.

    Kagan B. L. Hirakura Y. Azimov R. Azimova R. Lin M. (2002 ). The channel hypothesis of Alzheimer’s disease: current status. Peptides 23 1311–1315.

    Not in our library10.1016/s0196-9781(02)00067-0

  203. 203.

    Kakio A. Nishimoto S. Yanagisawa K. Kozutsumi Y. Matsuzaki K. (2002 ). Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry 241 7385–7390.

    Not in our library10.1021/bi0255874

  204. 204.

    Kakio A. Nishimoto S. I. Yanagisawa K. Kozutsumi Y. Matsuzaki K. (2001 ). Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid. J. Biol. Chem. 276 24985–24990.

    Not in our library10.1074/jbc.m100252200

  205. 205.

    Kamal A. Almenar-Queralt A. LeBlanc J. F. Roberts E. A. Goldstein L. S. (2001 ). Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature 414 643–648.

    Not in our library10.1038/414643

  206. 206.

    Kamerbeek C. B. Borroni V. Pediconi M. F. Sato S. B. Kobayashi T. Barrantes F. J. (2013 ). Antibody-induced acetylcholine receptor clusters inhabit liquid-ordered and liquid-disordered domains. Biophys. J. 150 1601–1611.

    Not in our library10.1016/j.bpj.2013.08.03

  207. 207.

    Kanfer J. N. Sorrentino G. Sitar D. S. (1999 ). Amyloid beta peptide membrane perturbation is the basis for its biological effects. Neurochem. Res. 24 1621–1630.

    Not in our library10.1023/a:1021172620295

  208. 208.

    Karlin A. Akabas M. H. (1995 ). Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins. Neuron 15 1231–1244.

    Not in our library10.1016/0896-6273(95)90004-7

  209. 209.

    Kawahara M. (2010 ). Neurotoxicity of β-amyloid protein: oligomerization, channel formation, and calcium dyshomeostasis. Curr. Pharm. Des. 16 2779–2789.

    Not in our library10.2174/138161210793176545

  210. 210.

    Kellner R. R. Baier C. J. Willig K. I. Hell S. W. Barrantes F. J. (2007 ). Nanoscale organization of nicotinic acetylcholine receptors revealed by stimulated emission depletion microscopy. Neuroscience 144 135–143.

    Not in our library10.1016/j.neuroscience.2006.08.071

  211. 211.

    Khan G. M. Tong M. Jhun M. Arora K. Nichols R. A. (2010 ). Beta-Amyloid activates presynaptic alpha7 nicotinic acetylcholine receptors reconstituted into a model nerve cell system: involvement of lipid rafts. Eur. J. Neurosci. 231 788–796.

    Not in our library10.1111/j.1460-9568.2010.07116.x

  212. 212.

    Kim H.-J. Moon W.-J. Han S.-H. (2013 ). Differential cholinergic pathway involvement in Alzheimer’s disease and subcortical ischemic vascular dementia. J. Alzheimers Dis. 35 129–136.

    Not in our library10.3233/jad-122320

  213. 213.

    Kim S. Yi J. Ko Y. (2006 ). Amyloid b Oligomerization Is Induced by Brain Lipid Rafts. J. Cell. Biochem. 99 878–889.

    Not in our library10.1002/jcb.20978

  214. 214.

    Kirsch C. Eckert G. P. Mueller W. E. (2002 ). Cholesterol attenuates the membrane perturbing properties of beta-amyloid peptides. Amyloid 9 149–159.

    Not in our library10.3109/13506120209114816

  215. 215.

    Kirsch C. Eckert G. P. Mueller W. E. (2003 ). Statin effects on cholesterol micro-domains in brain plasma membranes. Biochem. Pharmacol. 65 843–856.

    Not in our library10.1016/s0006-2952(02)01654-4

  216. 216.

    Klein W. L. Steine W. B. Jr. Teplow D. B. (2004 ). Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer’s disease. Neurobiol. Aging 25 569–580.

    Not in our library10.1016/j.neurobiolaging.2004.02.010

  217. 217.

    Kogel D. Copanaki E. Hartig U. Bottner S. Peters I. Muller W. E. (2008 ). “Modulation of membrane fluidity by omega 3 fatty acids: enhanced generation of sAPPalpha is required for the neuroprotective effects of DHA,” in The 38th Annual Meeting of the Society for Neuroscience, Washington, DC, 15–19.

    Not in our library

  218. 218.

    Kojro E. Gimpl G. Lammich S. Marz W. Fahrenholz F. (2001 ). Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. Proc. Natl. Acad. Sci. U.S.A. 98 5815–5820.

    Not in our library10.1073/pnas.081612998

  219. 219.

    Koo E. H. Squazzo S. L. (1994 ). Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J. Biol. Chem. 269 17386–17389.

    Not in our library

  220. 220.
    Phospholipids and Alzheimer’s Disease: Alterations, Mechanisms and Potential Biomarkers · 2013
    No notice
  221. 221.

    Kotler S. A. Walsh P. Brender J. R. Ramamoorthy A. (2014 ). Differences between amyloid-β aggregation in solution and on the membrane: insights into elucidation of the mechanistic details of Alzheimer’s disease. Chem. Soc. Rev. 19 6692–6700.

    Not in our library10.1039/c3cs60431d

  222. 222.

    Koudinov A. R. Koudinova N. V. (2004 ). Cholesterol homeostasis failure as a unifying cause of synaptic degeneration. J. Neurol. Sci. 229-230 233–240.

    Not in our library10.1016/j.jns.2004.11.036

  223. 223.

    Koudinova N. V. Koudinov A. R. Yavin E. (2000 ). Alzheimer’s Abeta1-40 peptide modulates lipid synthesis in neuronal cultures and intact rat fetal brain under normoxic and oxidative stress conditions. Neurochem. Res. 25 653–660.

    Not in our library10.1023/a:1007511120099

  224. 224.

    Kumar A. Singh A. Ekavali (2015 ). A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol. Rep. 67 195–203.

    Not in our library10.1016/j.pharep.2014.09.004

  225. 225.

    Lahdo R. De La Fournière-Bessueille L. (2004 ). Insertion of the amyloid precursor protein into lipid monolayers: effects of cholesterol and apolipoprotein E. Biochem. J. 382 987–994.

    Not in our library10.1042/bj20040777

  226. 226.

    Langui D. Girardot N. El Hachimi KH Allinquant B. Blanchard V. Pradier L. (2004 ). Subcellular topography of neuronal Abeta peptide in APPxPS1 transgenic mice. Am. J. Pathol. 165 1465–1477.

    Not in our library10.1016/s0002-9440(10)63405-0

  227. 227.

    Lashuel H. A. Hartley D. Petre B. M. Walz T. Lansbury P. T. Jr. (2002 ). Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418:291.

    Not in our library10.1038/418291a

  228. 228.

    Lauderback C. M. Hackett J. M. Keller J. N. Varadarajan S. Szweda L. Kindy M. (2001 ). Vulnerability of synaptosomes from apoE knock-out mice to structural and oxidative modifications induced by A beta(1-40): implications for Alzheimer’s disease. Biochemistry 240 2548–2554.

    Not in our library10.1021/bi002312k

  229. 229.

    Lazarevic-Pasti T. Leskovac A. Momic T. Petrovic S. Vasic V. (2017 ). Modulators of Acetylcholinesterase activity: from Alzheimer’s disease to anti-cancer drugs. Curr. Med. Chem. 24 3283–3309.

    Not in our library10.2174/0929867324666170705123509

  230. 230.

    Le Novère N. Changeux J. P. (1995 ). Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells. J Mol. Evol. 40 155–172.

    Not in our library10.1007/bf00167110

  231. 231.

    Lee A. G. (2003 ). Lipid - protein interactions in biological membranes: a structural perspective. Biochim. Biophys. Acta 1612 1–40.

    Not in our library10.1016/s0005-2736(03)00056-57

  232. 232.

    Lee D. H. S. Wang H.-Y. (2003 ). Differential physiologic responses of α7 nicotinic acetylcholine receptors to β-amyloid1–40 and β-amyloid1–42. J. Neurobiol. 55 25–30.

    Not in our library10.1002/neu.10203

  233. 233.

    Lee E. B. Leng L. Z. Zhang B. Kwong L. Trojanowski J. Q. Abel T. (2006 ). Targeting amyloid-β peptide (Aβ) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Aβ precursor protein (APP) transgenic mice. J. Biol. Chem. 281 4292–4299.

    Not in our library10.1074/jbc.m511018200

  234. 234.

    Lee S. J. Liyanage U. Bickel P. E. Xia W. Lansbury P. T. Jr. Kosik K. S. (1998 ). A detergent-insoluble membrane compartment contains A beta in vivo. Nat. Med. 4 730–734.

    Not in our library10.1038/nm0698-730

  235. 235.

    Levin E. D. Cauley M. Rezvani A. H. (2013 ). Improvement of attentional function with antagonism of nicotinic receptors in female rats. Eur. J. Pharmacol. 702 269–274.

    Not in our library10.1016/j.ejphar.2013.01.056

  236. 236.

    Li L. Cheung T. Chen J. Herrup K. (2011 ). A comparative study of five mouse models of Alzheimer’s disease: cell cycle events reveal new insights into neurons at risk for death. Int. J. Alzheimers Dis. 2011:171464.

    Not in our library10.4061/2011/171464

  237. 237.

    Lilja A. M. Porras O. Storelli E. Nordberg A. Marutle A. (2011 ). Functional interactions of fibrillar and oligomeric amyloid-β with alpha7 nicotinic receptors in Alzheimer’s disease. J. Alzheimers Dis. 23 335–347.

    Not in our library10.3233/jad-2010-101242

  238. 238.

    Lin H. Bhatia R. Lal R. (2001 ). Amyloid beta protein forms ion channels: implications for Alzheimer’s diseases pathophysiology. FASEB J. 15 2433–2444.

    Not in our library10.1096/fj.01-0377com

  239. 239.

    Lin M. S. Chen L. Y. Wang S. S. Chang Y. Chen W. Y. (2008 ). Examining the levels of ganglioside and cholesterol in cell membrane on attenuation the cytotoxicity of beta-amyloid peptide. Colloids Surf. B. Biointerfaces 65 172–177.

    Not in our library10.1016/j.colsurfb.2008.03.012

  240. 240.

    Lindstrom J. M. (2003 ). Nicotinic acetylcholine receptors of muscles and nerves: comparison of their structures, functional roles, and vulnerability to pathology. Ann. N.Y. Acad. Sci. 998 41–52.

    Not in our library10.1196/annals.1254.007

  241. 241.

    Liu Q. Kawai H. Berg D. K. (2001 ). Beta -Amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons. Proc. Natl. Acad. Sci. U.S.A. 98 4734–4739.

    Not in our library10.1073/pnas.081553598

  242. 242.

    Liu Q. Wu J. (2006 ). Neuronal nicotinic acetylcholine receptors serve as sensitive targets that mediate beta-amyloid neurotoxicity. Acta. Pharmacol. Sin. 27 1277–1286.

    Not in our library10.1111/j.1745-7254.2006.00430.x

  243. 243.

    Liu Q. Xie X. Emadi S. Sierks M. R. Wu J. (2015 ). A novel nicotinic mechanism underlies b -amyloid-induced neurotoxicity. Neuropharmacology 97 457–463.

    Not in our library10.1016/j.neuropharm.2015.04.025

  244. 244.

    Liu Q. Xie X. Lukas R. J. St John P. A. Wu J. (2013 ). A novel nicotinic mechanism underlies β-amyloid-induced neuronal hyperexcitation. J. Neurosci. 33 7253–7263.

    Not in our library10.1523/jneurosci.3235-12.2013

  245. 245.

    Liu R. Gu R. Qi X. Zhang T. Zhao Y. He Y. (2008 ). Decreased Nicotinic receptors and cognitive deficit in rats intracerebroventricularly injected with beta-amyloid peptide (1-42) and fed a high-cholesterol diet. J. Neurosci. Res. 86 183–193.

    Not in our library10.1002/jnr.21463

  246. 246.

    Lombardo S. Maskos U. (2014 ). Neuropharmacology Role of the nicotinic acetylcholine receptor in Alzheimer’s disease pathology and treatment. Neuropharmacology 96 255–262.

    Not in our library10.1016/j.neuropharm.2014.11.018

  247. 247.

    London E. (2005 ). How principles of domain formation in model membranes may explain ambiguities concerning lipidraft formation in cells. Biochim. Biophys. Acta 30 203–220.

    Not in our library10.1016/j.bbamcr.2005.09.002

  248. 248.

    Lukiw W. J. (2013 ). Alzheimer’s disease (AD) as a disorder of the plasma membrane. Front. Physiol. 4:24

    Not in our library10.3389/fphys.2013.00024

  249. 249.

    Ma K. Qian Y. (2019 ). Neuropeptides Alpha 7 nicotinic acetylcholine receptor and its effects on Alzheimer’s disease. Neuropeptides 73 96–106.

    Not in our library10.1016/j.npep.2018.12.003

  250. 250.

    Magni F. Galbusera C. Tremolada L. Ferrarese C. Kienle M. G. (2002 ). Characterisation of adducts of the lipid peroxidation product 4-hydroxy-2-nonenal and amyloid beta-peptides by liquid chromatography/electrospray ionisation mass spectrometry. Rapid. Commun. Mass. Spectrom. 16 1485–1493.

    Not in our library10.1002/rcm.743

  251. 251.

    Maia M. A. Sousa E. (2019 ). BACE-1 and γ-secretase as therapeutic targets for Alzheimer’s disease. Pharmaceuticals 12:41.

    Not in our library10.3390/ph12010041

  252. 252.

    Marchand S. Devillers-thie A. Pons S. Changeux J. Cartaud J. (2002 ). Rapsyn escorts the Nicotinic Acetylcholine receptor along the exocytic pathway via association with lipid rafts. J. Neurosci. 22 8891–8901.

    Not in our library10.1523/jneurosci.22-20-08891.2002

  253. 253.

    Mark R. Lovell M. A. Markesbery W. Koiiuchida I. Mattson P. (1997 ). A role for 4-Hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid- beta peptide. J. Neurochem. 68 255–264.

    Not in our library10.1046/j.1471-4159.1997.68010255.x

  254. 254.

    Marsh D. Barrantes F. J. (1978 ). Immobilized lipid in acetylcholine receptor-rich membranes from Torpedo marmorata. Proc. Natl. Acad. Sci. U.S.A. 75 4329–4333.

    Not in our library10.1073/pnas.75.9.4329

  255. 255.

    Martín V. Fabelo N. Santpere G. Puig B. Marín R. Ferrer I. (2010 ). Lipid alterations in lipid rafts from Alzheimer’s disease human brain cortex. J. Alzheimers. Dis. 19 489–502.

    Not in our library10.3233/jad-2010-1242

  256. 256.

    Martínez-Senac M. Villalaín J. Gómez-Fernández J. C. (1999 ). Structure of the Alzheimer beta-amyloid peptide (25-35) and its interaction with negatively charged phospholipid vesicles. Eur. J. Biochem. 265 744–753.

    Not in our library10.1046/j.1432-1327.1999.00775.x

  257. 257.

    Martorana A. Esposito Z. Koch G. (2010 ). Beyond the cholinergic hypothesis: do current drugs work in Alzheimer’s disease? CNS Neurosci. Ther. 16 235–245.

    Not in our library10.1111/j.1755-5949.2010.00175.x

  258. 258.

    Mason R. P. Shoemaker W. J. Shajenko L. Chambers T. E. Herbette L. G. (1992 ). Evidence for changes in the Alzheimer’s disease brain cortical membrane structure mediated by cholesterol. Neurobiol. Aging 13 413–419.

    Not in our library10.1016/0197-4580(92)90116-f

  259. 259.

    Massoulié J. (2002 ). The origin of the molecular diversity and functional anchoring of cholinesterases. Neurosignals 11 130–143.

    Not in our library10.1159/000065054

  260. 260.

    Massoulié J. Bon S. Perrier N. Falasca C. (2005 ). The C-terminal peptides of acetylcholinesterase: cellular trafficking, oligomerization and functional anchoring. Chem. Biol. Interact. 157-158 3–14.

    Not in our library10.1016/j.cbi.2005.10.002

  261. 261.

    Matsuzaki K. (2007 ). Physicochemical interactions of amyloid β -peptide with lipid bilayers. Biochim. Biophys. Acta 1768 1935–1942.

    Not in our library10.1016/j.bbamem.2007.02.009

  262. 262.

    Matsuzaki K. Kato K. Yanagisawa K. (2010 ). Abeta polymerization through interaction with membrane gangliosides. Biochim. Biophys. Acta 1801 868–877.

    Not in our library10.1016/j.bbalip.2010.01.008

  263. 263.

    McKay B. E. Placzek A. N. Dani J. A. (2007 ). Regulation of synaptic transmission and plasticity by neuronal nicotinic acetylcholine receptors. Biochem. Pharmacol. 74 1120–1133.

    Not in our library10.1016/j.bcp.2007.07.001

  264. 264.

    McLaurin J. Chakrabartty A. (1997 ). Characterization of the interactions of Alzheimer beta-amyloid peptides with phospholipid. Eur. J. Biochem. 1245 355–363.

    Not in our library10.1111/j.1432-1033.1997.t01-2-00355.x

  265. 265.

    McLaurin J. Franklin T. Fraser P. E. Chakrabartty A. (1998 ). Structural transitions associated with the interaction of Alzheimer beta-amyloid peptides with gangliosides. J. Biol. Chem. 273 4506–4515.

    Not in our library10.1074/jbc.273.8.4506

  266. 266.

    Mehta T. K. Dougherty J. J. Wu J. Choi C. H. Khan G. M. Nichols R. A. (2009 ). Defining pre-synaptic nicotinic receptors regulated by beta amyloid in mouse cortex and hippocampus with receptor null mutants. J. Neurochem. 109 1452–1458.

    Not in our library10.1111/j.1471-4159.2009.06070.x

  267. 267.

    Messi M. L. Renganathan M. Grigorenko E. Delbono O. (1997 ). Activation of alpha7 nicotinic acetylcholine receptor promotes survival of spinal cord motoneurons. FEBS Lett. 411 32–38.

    Not in our library10.1016/s0014-5793(97)00600-5

  268. 268.

    Mesulam M. M. Mufson E. J. Levey A. I. Wainer B. H. (1983 ). Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J. Comp. Neurol. 20 170–197.

    Not in our library10.1002/cne.902140206

  269. 269.

    Méthot N. Demers C. N. Baenziger J. E. (1995 ). Structure of both the ligand- and lipid-dependent channel-inactive states of the nicotinic acetylcholine receptor probed by FTIR spectroscopy and hydrogen exchange. Biochemistry 34 15142–15149.

    Not in our library10.1021/bi00046a021

  270. 270.

    Michikawa M. (2003 ). The role of cholesterol in pathogenesis of Alzheimer’s disease: dual metabolic interaction between amyloid β-protein and cholesterol. Mol. Neurobiol. 27 1–12.

    Not in our library10.1385/mn:27:1:1

  271. 271.

    Michikawa M. Gong J. S. Fan Q. W. Sawamura N. Yanagisawa K. (2001 ). A novel action of alzheimer’s amyloid beta-protein (Abeta): oligomeric Abeta promotes lipid release. J. Neurosci. 218 7226–7235.

    Not in our library10.1523/jneurosci.21-18-07226.2001

  272. 272.

    Middlemas D. S. Raftery M. A. (1987 ). Identification of Subunits of Acetylcholine Receptor That Interact with a Cholesterol Photoaffinity Probe. Biochemistry 126 1219–1223.

    Not in our library10.1021/bi00379a003

  273. 273.

    Milanesi L. Sheynis T. Xue W. F. Orlova E. V. Hellewell A. L. Jelinek R. (2012 ). Direct three-dimensional visualization of membrane disruption by amyloid fibrils. Proc. Natl. Acad. Sci. U.S.A. 109 20455–20460.

    Not in our library10.1073/pnas.1206325109

  274. 274.

    Minota S. Watanabe S. (1997 ). Inhibitory effects of arachidonic acid on nicotinic transmission in bullfrog sympathetic neurons. J. Neurophysiol. 178 2396–2401.

    Not in our library10.1152/jn.1997.78.5.2396

  275. 275.

    Molander-Melin M. Blennow K. Bogdanovic N. Dellheden B. Fredman P. (2005 ). Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent- resistant membrane domains. J. Neurochem. 92 171–182.

    Not in our library10.1111/j.1471-4159.2004.02849.x

  276. 276.

    Molinari E. J. Delbono O. Messi M. L. Renganathan M. Arneric S. P. Sullivan J. P. (1998 ). Up-regulation of human alpha7 nicotinic receptors by chronic treatment with activator and antagonist ligands. Eur. J. Pharmacol. 347 131–139.

    Not in our library10.1016/s0014-2999(98)00084-3

  277. 277.

    Morán M. A. Mufson E. J. Gómez-Ramos P. (1993 ). Colocalization of cholinesterases with beta amyloid protein in aged and Alzheimer’s brains. Acta Neuropathol. 85 362–369.

    Not in our library10.1007/bf00334445

  278. 278.

    Morley B. J. Happe H. K. (2000 ). Cholinergic receptors: dual roles in transduction and plasticity. Hear. Res. 147 104–112.

    Not in our library10.1016/s0378-5955(00)00124-6

  279. 279.

    Mosqueira A. Camino P. A. Barrantes F. J. (2018 ). Cholesterol modulates acetylcholine receptor diffusion by tuning confinement sojourns and nanocluster stability. Sci. Rep. 8:11974.

    Not in our library10.1038/s41598-018-30384

  280. 280.

    Mouritsen O. G. Bloom M. (1984 ). Mattress model of lipid-protein interactions in membranes. Biophys J. 46 141–153.

    Not in our library10.1016/s0006-3495(84)84007-2

  281. 281.

    Muir J. L. Page K. J. Sirinathsinghji D. J. Robbins T. W. Everitt B. J. (1993 ). Excitotoxic lesions of basal forebrain cholinergic neurons: effects on learning, memory and attention. Behav. Brain Res. 157 123–131.

    Not in our library10.1016/0166-4328(93)90128-d

  282. 282.

    Müller W. E. Kirsch C. Eckert G. P. (2001 ). Membrane-disordering effects of beta-amyloid peptides. Biochem. Soc. Trans. 29 617–623.

    Not in our library10.1042/bst0290617

  283. 283.

    Müller W. E. Koch S. Eckert A. Hartmann H. Scheuer K. (1995 ). β-amyloid peptide decreases membrane fluidity. Brain Res. 674 133–136.

    Not in our library10.1016/0006-8993(94)01463-r

  284. 284.

    Murray I. V. J. Liu L. Komatsu H. Uryu K. Xiao G. John A. (2007 ). Membrane-mediated amyloidogenesis and the promotion of oxidative lipid damage by amyloid beta proteins. J. Biol. Chem. 282 9335–9345.

    Not in our library10.1074/jbc.m608589200

  285. 285.

    Murray J. K. Farooqi B. Sadowsky J. D. Scalf M. Freund W. A. Smith L. M. (2005 ). Efficient synthesis of a beta-peptide combinatorial library with microwave irradiation. J. Am. Chem. Soc. 127 13271–13280.

    Not in our library10.1021/ja052733v

  286. 286.

    Nagele R. G. D’Andrea M. R. Anderson W. J. Wang H. Y. (2002 ). Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer’s disease. Neuroscience 110 199–211.

    Not in our library10.1016/s0306-4522(01)00460-2

  287. 287.

    Nagele R. G. D’Andrea M. R. Lee H. Venkataraman V. Wang H. Y. (2003 ). Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res. 971 197–209.

    Not in our library10.1016/s0006-8993(03)02361-8

  288. 288.

    Nagele R. G. Wegiel J. Venkataraman V. Imaki H. Wang K.-C. Wegiel J. (2004 ). Contribution of glial cells to the development of amyloid plaques in Alzheimer’s disease. Neurobiol. Aging 25 663–674.

    Not in our library10.1016/j.neurobiolaging.2004.01.007

  289. 289.

    Nalivaeva N. N. Turner A. J. (2016 ). Chemico-Biological Interactions AChE and the amyloid precursor protein (APP) -Cross-talk in Alzheimer’s disease. Chem. Biol. Interact. 259 301–306.

    Not in our library10.1016/j.cbi.2016.04.009

  290. 290.

    Narayanaswami V. Kim J. McNamee M. G. (1993 ). Protein-lipid interactions and Torpedo californica nicotinic acetylcholine receptor function. 1. Spatial disposition of cysteine residues in the γ subunit analyzed by fluorescence-quenching and energy-transfer measurements. Biochemistry 32 12413–12419.

    Not in our library10.1021/bi00097a020

  291. 291.

    Narayanaswami V. McNamee M. G. (1993 ). Protein-lipid interactions and Torpedo californica nicotinic acetylcholine receptor function. 2. Membrane fluidity and ligand-mediated alteration in the accessibility of gamma subunit cysteine residues to cholesterol. Biochemistry 123 12420–12427.

    Not in our library10.1021/bi00097a021

  292. 292.

    Nashmi R. Dickinson M. E. McKinney S. Jareb M. Labarca C. Fraser S. E. (2003 ). Assembly of alpha4beta2 nicotinic acetylcholine receptors assessed with functional fluorescently labeled subunits: effects of localization, trafficking, and nicotine-induced upregulation in clonal mammalian cells and in cultured midbrain neurons. J. Neurosci. 23 11554–11567.

    Not in our library10.1523/jneurosci.23-37-11554.2003

  293. 293.

    Näslund J. Haroutunian V. Mohs R. Davis K. L. Davies P. Greengard P. (2000 ). Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283 1571–1577.

    Not in our library10.1001/jama.283.12.1571

  294. 294.

    Näslund J. Schierhorn A. Hellman U. Lannfelt L. Roses A. D. Tjernberg L. O. (1994 ). Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc. Natl. Acad. Sci. U.S.A. 91 8378–8382.

    Not in our library10.1073/pnas.91.18.8378

  295. 295.

    Navaratnam D. S. Fernando F. S. Priddle J. D. Giles K. Clegg S. M. Pappin D. J. (2000 ). Hydrophobic protein that copurifies with human brain acetylcholinesterase: amino acid sequence, genomic organization, and chromosomal localization. J. Neurochem. 74 2146–2153.

    Not in our library10.1046/j.1471-4159.2000.0742146.x

  296. 296.

    Nees F. (2015 ). The nicotinic cholinergic system function in the human brain. Neuropharmacology 96 289–301.

    Not in our library10.1016/j.neuropharm.2014.10.021

  297. 297.

    Nicolson G. L. (2014 ). The fluid-mosaic model of membrane structure?: still relevant to understanding the structure, function and dynamics of biological membranes after more than 40 years. Biochim. Biophys. Acta. 1838 1451–1466.

    Not in our library10.1016/j.bbamem.2013.10.019

  298. 298.

    Niu X. Zhang X. Xie J. Zhang X. (2012 ). Acetylcholinesterase blocks cleavage of APP by γ-secretase in 293 cells and mouse brain. Mol. Neurodegener. 7(Suppl. 1):S11

    Not in our library10.1186/1750-1326-7-s1-s11

  299. 299.

    Nordberg A. Lundqvist H. Hartvig P. Lilja A. Långström B. (1995 ). Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains–in vivo assessment using positron emission tomography. Alzheimer Dis. Assoc. Disord. 9 21–27.

    Not in our library10.1097/00002093-199505000-00006

  300. 300.

    Nunomura A. Tamaoki T. Tanaka K. Motohashi N. Nakamura M. Hayashi T. (2010 ). Intraneuronal amyloid beta accumulation and oxidative damage to nucleic acids in Alzheimer disease. Neurobiol. Dis. 37 731–737.

    Not in our library10.1016/j.nbd.2009.12.012

  301. 301.

    Nurowska E. Ruzzier F. (1996 ). Corticosterone modifies the murine muscle acetylcholine receptor channel kinetics. Neuroreport 8 77–80.

    Not in our library10.1097/00001756-199612200-00016

  302. 302.

    Nurowska E. Ruzzier F. (2002 ). Modulation of acetylcholine receptor channel kinetics by hydrocortisone. Biochim. Biophys. Acta 1564 14–20.

    Not in our library10.1016/s0005-2736(02)00356-5

  303. 303.

    Ochoa E. L. Dalziel A. W. McNamee M. G. (1983 ). Reconstitution of acetylcholine receptor function in lipid vesicles of defined composition. Biochim. Biophys. Acta 1727 151–162.

    Not in our library10.1016/0005-2736(83)90379-6

  304. 304.

    Opazo C. Huang X. Cherny R. A. Moir R. D. Roher A. E. White A. R. (2002 ). Metalloenzyme-like activity of Alzheimer’s disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to Neurotoxic H(2)O(2). J. Biol. Chem. 277 40302–40308.

    Not in our library10.1074/jbc.m206428200

  305. 305.

    Oshikawa J. Toya Y. Fujita T. Egawa M. Kawabe J. Umemura S. (2003 ). Nicotinic acetylcholine receptor alpha 7 regulates cAMP signal within lipid rafts. Am. J. Physiol. Cell. Physiol. 285 C567–C574.

    Not in our library10.1152/ajpcell.00422.2002

  306. 306.

    Oshima N. Morishima-kawashima M. Yamaguchi H. Yoshimura M. Schenk D. Ihara Y. (2001 ). Accumulation of amyloid beta - protein in the low - density membrane domain accurately reflects the extent of beta -amyloid deposition in the Brain. Am. J. Pathol. 158 2209–2218.

    Not in our library10.1016/s0002-9440(10)64693-7

  307. 307.

    Palop J. J. Mucke L. (2010 ). Amyloid-beta-induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neural networks. Nat. Neurosci. 13 812–818.

    Not in our library10.1038/nn.2583

  308. 308.

    Parri H. R. Hernandez C. M. Dineley K. T. (2011 ). Research update: Alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer’s disease. Biochem. Pharmacol. 82 931–942.

    Not in our library10.1016/j.bcp.2011.06.039

  309. 309.

    Parvathy S. Hussain I. Karran E. H. Turner A. J. Hooper N. M. (1999 ). Cleavage of Alzheimer’s amyloid precursor protein by alpha. -secretase occurs at the surface of neuronal cells. Biochemistry 38 9728–9734.

    Not in our library10.1021/bi9906827

  310. 310.

    Paterson D. Nordberg A. (2000 ). Neuronal nicotinic receptors in the human brain. Prog. Neurobiol. 61 75–111.

    Not in our library10.1016/s0301-0082(99)00045-3

  311. 311.

    Pediconi M. F. Gallegos C. E. Barrantes F. J. (2004 ). Metabolic cholesterol depletion hinders cell-surface trafficking of the nicotinic acetylcholine receptor. Neuroscience 128 239–249.

    Not in our library10.1016/j.neuroscience.2004.06.007

  312. 312.

    Peña V. B. Bonini I. C. Antollini S. S. Kobayashi T. Barrantes F. J. (2011 ). A7-Type Acetylcholine Receptor Localization and Its Modulation By Nicotine and Cholesterol in Vascular Endothelial Cells. J. Cell. Biochem. 112 3276–3288.

    Not in our library10.1002/jcb.23254

  313. 313.

    Perez R. G. Soriano S. Hayes J. D. Ostaszewski B. Xia W. Selkoe D. J. (1999 ). Mutagenesis identifies new signals for beta-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Abeta42. J. Biol. Chem. 274 18851–18856.

    Not in our library10.1074/jbc.274.27.18851

  314. 314.

    Perillo V. L. Peñalva D. A. Vitale A. J. Barrantes F. J. Antollini S. S. (2016 ). Transbilayer asymmetry and sphingomyelin composition modulate the preferential membrane partitioning of the nicotinic acetylcholine receptor in Lo domains. Arch. Biochem. Biophys. 591 76–86.

    Not in our library10.1016/j.abb.2015.12.003

  315. 315.

    Perrier A. L. Massoulié J. Krejci E. (2002 ). PRiMA: the membrane anchor of acetylcholinesterase in the brain. Neuron. 33 275–285.

    Not in our library10.1016/s0896-6273(01)00584-0

  316. 316.

    Perry E. K. Blessed G. Tomlinson B. E. Perry R. H. Crow T. J. Cross A. J. (1981 ). Neurochemical activities in human temporal lobe related to aging and Alzheimer-type changes. Neurobiol. Aging 2 251–266.

    Not in our library10.1016/0197-4580(81)90032-4

  317. 317.

    Perry E. K. Curtis M. Dick D. J. Candy J. M. Atack J. R. Bloxham C. A. (1985 ). Cholinergic correlates of cognitive impairment in Parkinson’s disease: comparisons with Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry 48 413–421.

    Not in our library10.1136/jnnp.48.5.413

  318. 318.

    Perry E. K. Johnson M. Kerwin J. M. Piggott M. A. Court J. A. Shaw P. J. (1992 ). Convergent cholinergic activities in aging and Alzheimer’s disease. Neurobiol. Aging 13 393–400.

    Not in our library10.1016/0197-4580(92)90113-c

  319. 319.

    Perry E. K. Perry R. H. Smith C. J. Dick D. J. Candy J. M. Edwardson J. A. (1987 ). Nicotinic receptor abnormalities in Alzheimer’s and Parkinson’s diseases. J. Neurol. Neurosurg. Psychiatry 50 806–809.

    Not in our library10.1136/jnnp.50.6.806

  320. 320.

    Perry G. Lipphardt S. Mulvihill P. Kancherla M. Mijares M. Gambetti P. (1988 ). Amyloid precursor protein in senile plaques of Alzheimer disease. Lancet 2 746–751.

    Not in our library10.1016/s0140-6736(88)90219-x

  321. 321.

    Peters I. Igbavboa U. Schütt T. Haidari S. Hartig U. Rosello X. (2009 ). The interaction of beta-amyloid protein with cellular membranes stimulates its own production. Biochim. Biophys. Acta 1788 964–972.

    Not in our library10.1016/j.bbamem.2009.01.012

  322. 322.

    Petersen R. C. (1977 ). Scopolamine induced learning failures in man. Psychopharmacology 52 283–289.

    Not in our library10.1007/bf00426713

  323. 323.

    Pettit D. L. Shao Z. Yakel J. L. (2001 ). Beta-Amyloid(1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice. J. Neurosci. 21:RC120.

    Not in our library10.1523/jneurosci.21-01-j0003.2001

  324. 324.

    Phinney A. L. Horne P. Yang J. Janus C. Bergeron C. Westaway D. (2003 ). Mouse models of Alzheimer’s disease: the long and filamentous road. Neurol. Res. 25 590–600.

    Not in our library10.1179/016164103101202020

  325. 325.

    Piomelli D. Astarita G. Rapaka R. (2007 ). A neuroscientist’s guide to lipidomics. Nat. Rev. Neurosci. 8 743–754.

    Not in our library10.1038/nrn2233

  326. 326.

    Plant L. D. Boyle J. P. Smith I. F. Peers C. Pearson H. A. (2003 ). The production of amyloid beta peptide is a critical requirement for the viability of central neurons. J. Neurosci. 23 5531–5535.

    Not in our library10.1523/jneurosci.23-13-05531.2003

  327. 327.
    Alpha7 Nicotinic Acetylcholine Receptor Is a Target in Pharmacology and Toxicology · 2012
    No notice
  328. 328.

    Pollard H. B. Arispe N. Rojas E. (1995 ). Ion Channel Hypothesis for Alzheimer Amyloid Peptide Neurotoxicity. Cell. Mol. Neurobiol. 15 513–526.

    Not in our library10.1007/bf02071314

  329. 329.

    Poveda J. A. Encinar J. A. Fernández A. M. Mateo C. R. Ferragut J. A. González-Ros J. M. (2002 ). Segregation of phosphatidic acid-rich domains in reconstituted acetylcholine receptor membranes. Biochemistry 41 12253–12262.

    Not in our library10.1021/bi0200099

  330. 330.

    Poveda J. A. Fernández A. M. Encinar J. A. (2008 ). Protein-promoted membrane domains. Biochim. Biophys. Acta 1778 1583–1590.

    Not in our library10.1016/j.bbamem.2008.01.021

  331. 331.

    Puglielli L. Konopka G. Pack-Chung E. Ingano L. A. M. Berezovska O. Hyman B. T. (2001 ). Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid β-peptide. Nat. Cell. Biol. 3 905–912.

    Not in our library10.1038/ncb1001-905

  332. 332.

    Puzzo D. Arancio O. (2013 ). Amyloid-β peptide: Dr. Jekyll or Mr. Hyde? J. Alzheimers Dis. 33 S111–S120.

    Not in our library10.3233/jad-2012-129033

  333. 333.

    Puzzo D. Gulisano W. Arancio O. Palmeri A. (2015 ). The keystone of Alzheimer pathogenesis might be sought in Aβ physiology. Neuroscience 307 26–36.

    Not in our library10.1016/j.neuroscience.2015.08.039

  334. 334.

    Puzzo D. Privitera L. Fa’ M. Staniszewski A. Hashimoto G. Aziz F. (2011 ). Endogenous amyloid-β is necessary for hippocampal synaptic plasticity and memory. Ann. Neurol. 69 819–830.

    Not in our library10.1002/ana.22313

  335. 335.

    Puzzo D. Privitera L. Leznik E. Fà M. Staniszewski A. Palmeri A. (2008 ). Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J. Neurosci. 28 14537–14545.

    Not in our library10.1523/jneurosci.2692-08.2008

  336. 336.

    Qiang W. Yau W. M. Schulte J. (2014 ). Fibrillation of β amyloid peptides in the presence of phospholipid bilayers and the consequent membrane disruption. Biochim. Biophys. Acta 1848 266–276.

    Not in our library10.1016/j.bbamem.2014.04.011

  337. 337.

    Quesada O. González-Freire C. Ferrer M. C. Colón-Sáez J. O. Fernández-García E. Mercado J. (2016 ). Uncovering the lipidic basis for the preparation of functional nicotinic acetylcholine receptor detergent complexes for structural studies. Sci. Rep. 19:32766.

    Not in our library10.1038/srep32766

  338. 338.

    Quinn P. J. (2002 ). Plasma membrane phospholipid asymmetry. Subcell Biochem. 36 39–60.

    Not in our library10.1007/0-306-47931-1_3

  339. 339.

    Reid P. C. Urano Y. Kodama T. Hamakubo T. (2007 ). Alzheimer’s Disease?: cholesterol, membrane rafts, isoprenoids and statins. J. Cell. Mol. Med. 11 383–392.

    Not in our library10.1111/j.1582-4934.2007.00054.x

  340. 340.

    Relini A. Marano N. Gliozzi A. (2013 ). Misfolding of amyloidogenic proteins and their interactions with membranes. Biomolecules 27 20–55.

    Not in our library10.3390/biom4010020

  341. 341.

    Relini A. Marano N. Gliozzi A. (2014 ). Probing the interplay between amyloidogenic proteins and membranes using lipid monolayers and bilayers. Adv. Colloid Interface Sci. 207 81–92.

    Not in our library10.1016/j.cis.2013.10.015

  342. 342.

    Reyes A. E. Perez D. R. Alvarez A. Garrido J. Gentry M. K. Doctor B. P. (1997 ). A monoclonal antibody against acetylcholinesterase inhibits the formation of amyloid fibrils induced by the enzyme. Biochem. Biophys. Res. Commun. 232 652–655.

    Not in our library10.1006/bbrc.1997.6357

  343. 343.

    Roccamo A. M. Pediconi M. F. Aztiria E. Zanello L. Wolstenholme A. Barrantes F. J. (1999 ). Cells defective in sphingolipids biosynthesis express low amounts of muscle nicotinic acetylcholine receptor. Eur. J. Neurosci. 11 1615–1623.

    Not in our library10.1046/j.1460-9568.1999.00574.x

  344. 344.

    Rondelli V. Brocca P. Motta S. Messa M. Colombo L. Salmona M. (2016 ). Amyloid - β Peptides in interaction with raft-mime model membranes: a neutron reflectivity insight. Sci. Rep. 16:20997.

    Not in our library10.1038/srep20997

  345. 345.

    Rosenblum W. I. (2014 ). Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult. Neurobiol. Aging 35 969–974.

    Not in our library10.1016/j.neurobiolaging.2013.10.085

  346. 346.

    Roth G. S. Joseph J. A. Mason R. P. (1995 ). Membrane alterations as causes of impaired signal transduction in Alzheimer’s disease and aging. Trends. Neurosci. 18 203–206.

    Not in our library10.1016/0166-2236(95)93902-a

  347. 347.
    Lipid Rafts: Linking Alzheimer′s Amyloid‐ β Production, Aggregation, and Toxicity at Neuronal Membranes · 2010
    No notice
  348. 348.

    Sáez-Valero J. Sberna G. McLean C. A. Small D. H. (1999 ). Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer’s disease. J. Neurochem. 72 1600–1608.

    Not in our library10.1046/j.1471-4159.1999.721600.x

  349. 349.

    Sargent P. B. Bryan G. K. Streichert L. C. Garrett E. N. (1991 ). Denervation does not alter the number of neuronal bungarotoxin binding sites on autonomic neurons in the frog cardiac ganglion. J. Neurosci. 11 3610–3623.

    Not in our library10.1523/jneurosci.11-11-03610.1991

  350. 350.

    Sargent P. B. Garrett E. N. (1995 ). The characterization of alpha-bungarotoxin receptors on the surface of parasympathetic neurons in the frog heart. Brain Res. 680 99–107.

    Not in our library10.1016/0006-8993(95)00250-t

  351. 351.

    Sarter M. Bruno J. P. (1997 ). Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. Brain Res. 23 28–46.

    Not in our library10.1016/s0165-0173(96)00009-4

  352. 352.

    Sarter M. Paolone G. (2011 ). Deficits in attentional control: cholinergic mechanisms and circuitry-based treatment approaches. Behav. Neurosci. 125 825–835.

    Not in our library10.1037/a0026227

  353. 353.

    Sasahara K. Morigaki K. Shinya K. (2013 ). Effects of membrane interaction and aggregation of amyloid β-peptide on lipid mobility and membrane domain structure. Phys. Chem. Chem. Phys. 15 8929–8939.

    Not in our library10.1039/c3cp44517h

  354. 354.

    Schmidt J. T. Freeman J. A. (1980 ). Electrophysiologic evidence that retinotectal synaptic transmission in the goldfish is nicotinic cholinergic. Brain Res. 187 129–142.

    Not in our library10.1016/0006-8993(80)90499-0

  355. 355.

    Scholze P. Ciuraszkiewicz A. Groessl F. Orr-Urtreger A. McIntosh J. M. Huck S. (2011 ). α4β2 nicotinic acetylcholine receptors in the early postnatal mouse superior cervical ganglion. Dev. Neurobiol. 71 390–399.

    Not in our library10.1002/dneu.20870

  356. 356.

    Sciacca M. F. Kotler S. A. Brender J. R. Chen J. Lee D. K. Ramamoorthy A. (2012 ). Two-step mechanism of membrane disruption by Aβ through membrane fragmentation and pore formation. Biophys. J. 103 702–710.

    Not in our library10.1016/j.bpj.2012.06.045

  357. 357.

    Seghezza S. Diaspro A. Canale C. Dante S. (2014 ). Cholesterol drives aβ(1-42) interaction with lipid rafts in model membranes. Langmuir 30 13934–13941.

    Not in our library10.1021/la502966m

  358. 358.

    Sepúlveda F. J. Fierro H. Fernandez E. Castillo C. Peoples R. W. Opazo C. (2014 ). Nature of the neurotoxic membrane actions of amyloid-β on hippocampal neurons in Alzheimer’s disease. Neurobiol. Aging 5 472–481.

    Not in our library10.1016/j.neurobiolaging.2013.08.035

  359. 359.

    Serrano-Pozo A. Frosch M. P. Masliah E. Hyman B. T. (2011 ). Neuropathological alterations in Alzheimer disease. Cold. Spring. Harb. Perspect. Med. 1:a006189.

    Not in our library10.1101/cshperspect.a006189

  360. 360.

    Shankar G. M. Li S. Mehta T. H. Garcia-Munoz A. Shepardson N. E. Smith I. (2008 ). Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat. Med. 14 837–842.

    Not in our library10.1038/nm1782

  361. 361.

    Sharma G. Vijayaraghavan S. (2001 ). Nicotinic cholinergic signaling in hippocampal astrocytes involves calcium-induced calcium release from intracellular stores. Proc. Natl. Acad. Sci. U.S.A. 98 4148–4153.

    Not in our library10.1073/pnas.071540198

  362. 362.

    Sharp L. Salari R. Brannigan G. (2019 ). Boundary lipids of the nicotinic acetylcholine receptor: spontaneous partitioning via coarse-grained molecular dynamics simulation. Biochim. Biophys. Acta. Biomembr. 1861 887–896.

    Not in our library10.1016/j.bbamem.2019.01.005

  363. 363.

    Shen J. Wu J. (2015 ). Nicotinic cholinergic mechanisms in Alzheimer’s disease. Int. Rev. Neurobiol. 124 275–292.

    Not in our library10.1016/bs.irn.2015.08.00

  364. 364.

    Shen J. X. Yakel J. L. (2009 ). Nicotinic acetylcholine receptor-mediated calcium signaling in the nervous system. Acta Pharmacol. Sin. 30 673–680.

    Not in our library10.1038/aps.2009.64

  365. 365.

    Shimohama S. Taniguchi T. Fujiwara M. Kameyama M. (1986 ). Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer-type dementia. J. Neurochem. 46 288–293.

    Not in our library10.1111/j.1471-4159.1986.tb12960.x

  366. 366.

    Shringarpure R. Grune T. Sitte N. Davies K. J. (2000 ). 4-Hydroxynonenal-modified amyloid-beta peptide inhibits the proteasome: possible importance in Alzheimer’s disease. Cell. Mol. Life Sci. 57 1802–1809.

    Not in our library10.1007/pl00000660

  367. 367.

    Silveyra M. X. Evin G. Montenegro M. F. Vidal C. J. Martínez S. Culvenor J. G. (2008 ). Presenilin 1 interacts with acetylcholinesterase and alters its enzymatic activity and glycosylation. Mol. Cell. Biol. 28 2908–2919.

    Not in our library10.1128/mcb.02065-2067

  368. 368.

    Silveyra M. X. García-Ayllón M. S. Serra-Basante C. Mazzoni V. García-Gutierrez M. S. Manzanares J. (2012 ). Changes in acetylcholinesterase expression are associated with altered presenilin-1 levels. Neurobiol. Aging 33 627–637.

    Not in our library10.1016/j.neurobiolaging.2011.04.006

  369. 369.

    Simons K. Ikonen E. (1997 ). Functional rafts in cell membranes. Nature 387 569–572.

    Not in our library10.1038/42408

  370. 370.

    Simons K. van Meer G. (1988 ). Lipid sorting in epithelial cells. Biochemistry 23 6197–6202.

    Not in our library10.1021/bi00417a001

  371. 371.

    Simons M. Keller P. De Strooper B. Beyreuther K. Dotti C. G. Simons K. (1998 ). Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. U.S.A. 95 6460–6464.

    Not in our library10.1073/pnas.95.11.6460

  372. 372.

    Singer A. S. J. Nicolson G. L. (1972 ). The Fluid Mosaic Model of the Structure of Cell Membranes. Science 175 720–731.

    Not in our library10.1126/science.175.4023.720

  373. 373.

    Small D. H. Maksel D. Kerr M. L. Ng J. Hou X. Chu C. (2007 ). The b -amyloid protein of Alzheimer’s disease binds to membrane lipids but does not bind to the a 7 nicotinic acetylcholine receptor. J. Neurochem. 101 1527–1538.

    Not in our library10.1111/j.1471-4159.2006.04444.x

  374. 374.

    Small D. H. Michaelson S. Sberna G. (1996 ). Non-classical actions of cholinesterases: role in cellular differentiation, tumorigenesis and Alzheimer’s disease. Neurochem. Int. 28 453–483.

    Not in our library10.1016/0197-0186(95)00099-2

  375. 375.

    Sonnino S. Prinetti A. (2013 ). Membrane domains and the “lipid raft” concept. Curr Med Chem. 20 4–21.

    Not in our library10.2174/0929867311320010003

  376. 376.

    Staneva G. Puff N. Stanimirov S. Tochev T. Angelova M. I. Seigneuret M. (2018 ). The Alzheimer’s disease amyloid-β peptide affects the size-dynamics of raft-mimicking Lo domains in GM1-containing lipid bilayers. Soft. Matter. 14 9609–9618.

    Not in our library10.1039/c8sm01636d

  377. 377.

    Stefani M. (2010 ). Biochemical and biophysical features of both oligomer/fibril and cell membrane in amyloid cytotoxicity. FEBS J. 277 4602–4613.

    Not in our library10.1111/j.1742-4658.2010.07889.x

  378. 378.

    Stetzkowski-Marden F. Gaus K. Recouvreur M. Cartaud A. Cartaud J. (2006a ). Agrin elicits membrane lipid condensation at sites of acetylcholine receptor clusters in C2C12 myotubes. J. Lipid. Res. 47 2121–2133.

    Not in our library10.1194/jlr.m600182-jlr200

  379. 379.

    Stetzkowski-Marden F. Recouvreur M. Camus G. Cartaud A. Marchand S. Cartaud J. (2006b ). Rafts are required for acetylcholine receptor clustering. J. Mol. Neurosci. 30 37–38.

    Not in our library10.1385/jmn:30:1:37

  380. 380.

    Subasinghe S. Unabia S. Barrow C. J. Mok S. S. Aguilar M. I. Small D. H. (2003 ). Cholesterol is necessary both for the toxic effect of Abeta peptides on vascular smooth muscle cells and for Abeta binding to vascular smooth muscle cell membranes. J. Neurochem. 84 471–479.

    Not in our library10.1046/j.1471-4159.2003.01552.x

  381. 381.

    Sun J. Roy S. (2018 ). The physical approximation of APP and BACE-1: a key event in alzheimer’s disease pathogenesis. Dev. Neurobiol. 78 340–347.

    Not in our library10.1002/dneu.22556

  382. 382.

    Sunshine C. McNamee M. G. (1992 ). Lipid modulation of nicotinic acetylcholine receptor function: the role of neutral and negatively charged lipids. Biochim. Biophys. Acta 1108 240–246.

    Not in our library10.1016/0005-2736(92)90031-g

  383. 383.

    Sunshine C. McNamee M. G. (1994 ). Lipid modulation of nicotinic acetylcholine receptor function: the role of membrane lipid composition and fluidity. Biochim. Biophys. Acta 1191 59–64.

    Not in our library10.1016/0005-2736(94)90233-x

  384. 384.

    Tan J. Z. A. Gleeson P. A. (2019 ). The role of membrane trafficking in the processing of amyloid precursor protein and production of amyloid peptides in Alzheimer’s disease. BBA - Biomembr. 1861 697–712.

    Not in our library10.1016/j.bbamem.2018.11.013

  385. 385.

    Tapiola T. Pirttilä T. Mehta P. D. Alafuzofff I. Lehtovirta M. Soininen H. (2000 ). Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer’s disease. Neurobiol. Aging 21 735–740.

    Not in our library10.1016/s0197-4580(00)00164-0

  386. 386.

    Tenchov B. G. MacDonald R. C. Siegel D. P. (2006 ). Cubic phases in phosphatidylcholine-cholesterol mixtures: cholesterol as membrane “fusogen”. Biophys. J. 91 2508–2516.

    Not in our library10.1529/biophysj.106.083766

  387. 387.

    Terzi E. Hölzemann G. Seelig J. (1997 ). Interaction of Alzheimer beta-amyloid peptide(1-40) with lipid membranes. Biochemistry 36 14845–14852.

    Not in our library10.1021/bi971843e

  388. 388.

    Thomsen M. S. Andreasen J. T. Arvaniti M. Kohlmeier K. A. (2016 ). Nicotinic Acetylcholine receptors in the pathophysiology of Al zheimer’s disease: the role of protein-protein interactions in current and future treatment. Curr. Pharm. Des. 22 2015–2034.

    Not in our library10.2174/1381612822666160127112357

  389. 389.

    Thornton E. Vink R. Blumbergs P. C. Van Den Heuvel C. (2006 ). Soluble amyloid precursor protein alpha reduces neuronal injury and improves functional outcome following diffuse traumatic brain injury in rats. Brain Res. 1094 38–46.

    Not in our library10.1016/j.brainres.2006.03.107

  390. 390.

    Tozaki H. Matsumoto A. Kanno T. Nagai K. Nagata T. Yamamoto S. (2002 ). The inhibitory and facilitatory actions of amyloid-beta peptides on nicotinic ACh receptors and AMPA receptors. Biochem. Biophys. Res. Commun. 294 42–45.

    Not in our library10.1016/s0006-291x(02)00429-421

  391. 391.

    Turner P. R. O’Connor K. Tate W. P. Abraham W. C. (2003 ). Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol. 70 1–32.

    Not in our library10.1016/s0301-0082(03)00089-3

  392. 392.

    Unwin N. (2005 ). Refined structure of the nicotinic acetylcholine receptor at 4A resolution. J. Mol. Biol. 346 967–989.

    Not in our library10.1016/j.jmb.2004.12.031

  393. 393.

    Uranga R. M. Alza N. P. Conde M. A. Antollini S. S. Salvador G. A. (2017 ). Phosphoinositides: two-path signaling in neuronal response to Oligomeric amyloid β peptide. Mol. Neurobiol. 54 3236–3252.

    Not in our library10.1007/s12035-016-9885-9883

  394. 394.

    van Meer G. (2011 ). Dynamic transbilayer lipid asymmetry. Cold Spring Harb. Perspect. Biol. 3:004671.

    Not in our library10.1101/cshperspect.a004671

  395. 395.

    Vestergaard M. Hamada T. Morita M. Takagi M. (2010 ). Cholesterol, Lipids, Amyloid Beta, and Alzheimer’ s. Curr. Alzheimer Res. 7 262–270.

    Not in our library10.2174/156720510791050821

  396. 396.

    Vetrivel K. S. Cheng H. Kim S. Chen Y. Barnes N. Y. Parent A. T. (2005 ). Spatial segregation of gamma-secretase and substrates in distinct membrane domains. J. Biol. Chem. 280 25892–25900.

    Not in our library10.1074/jbc.m503570200

  397. 397.

    Vetrivel K. S. Cheng H. Lin W. Sakurai T. Li T. Nukina N. (2004 ). Association of γ-secretase with lipid rafts in post-Golgi and endosome membranes. J. Biol. Chem. 279 44945–44954.

    Not in our library10.1074/jbc.m407986200

  398. 398.

    Vetrivel K. S. Thinakaran G. (2006 ). Amyloidogenic processing of beta-amyloid precursor protein in intracellular compartments. Neurology 66 69–73.

    Not in our library10.1212/01.wnl.0000192107.17175.39

  399. 399.

    Villar M. T. Artigues A. Ferragut J. A. Gonzalez-Ros J. M. (1988 ). Phospholipase A2 hydrolysis of membrane phospholipids causes structural alteration of the nicotinic acetylcholine receptor. Biochim. Biophys. Acta 938 35–43.

    Not in our library10.1016/0005-2736(88)90119-8

  400. 400.

    Wahrle S. Das P. Nyborg A. C. Mclendon C. Shoji M. Kawarabayashi T. (2002 ). Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol. Dis. 9 11–23.

    Not in our library10.1006/nbdi.2001.0470

  401. 401.

    Wakabayashi M. Okada T. Kozutsumi Y. Matsuzaki K. (2005 ). GM1 ganglioside-mediated accumulation of amyloid beta-protein on cell membranes. Biochem. Biophys. Res. Commun. 328 1019–1023.

    Not in our library10.1016/j.bbrc.2005.01.060

  402. 402.

    Wang H.-Y. Lee D. H. Davis C. B. Shank R. P. (2000a ). Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. J. Neurochem. 75 1155–1161.

    Not in our library10.1046/j.1471-4159.2000.0751155.x

  403. 403.

    Wang H.-Y. Lee D. H. S. D’Andrea M. R. Peterson P. A. Shank R. P. Reitz A. B. (2000b ). β-amyloid1–42 binds to α7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer’s disease pathology. J. Biol. Chem. 275 5626–5632.

    Not in our library10.1074/jbc.275.8.5626

  404. 404.

    Wang H. Y. Li W. Benedetti N. J. Lee D. H. (2003 ). Alpha 7 nicotinic acetylcholine receptors mediate beta-amyloid peptide-induced tau protein phosphorylation. J. Biol. Chem. 278 1547–1553.

    Not in our library10.1074/jbc.m212532200

  405. 405.

    Wang H. Y. Stucky A. Liu J. Shen C. Trocme-Thibierge C. Morain P. (2009 ). Dissociating beta-amyloid from alpha 7 nicotinic acetylcholine receptor by a novel therapeutic agent, S 24795, normalizes alpha 7 nicotinic acetylcholine and NMDA receptor function in Alzheimer’s disease brain. J. Neurosci. 229 10961–10973.

    Not in our library10.1523/jneurosci.6088-08.2009

  406. 406.

    Wang Y. Qu D. Wang K. (2016 ). Therapeutic approaches to Alzheimer’s disease through stimulating of non-amyloidogenic processing of amyloid precursor protein. Eur. Rev. Med. Pharmacol. Sci. 20 2389–2403.

    Not in our library

  407. 407.
    Biological membranes · 2015
    No notice
  408. 408.

    Wen P.-C. Mahinthichaichan P. Trebesch N. Jiang T. Zhao Z. Shinn E. (2018 ). Microscopic view of lipids and their diverse biological functions. Curr. Opin. Struct. Biol. 51 177–186.

    Not in our library10.1016/j.sbi.2018.07.003

  409. 409.

    Wenk G. L. (1997 ). The nucleus basallis magnocellularis cholinergic system: one hundred years of progress. Neurobiol. Learn. Mem. 67 85–95.

    Not in our library10.1006/nlme.1996.3757

  410. 410.

    Wenz J. J. Barrantes F. J. (2005 ). Nicotinic acetylcholine receptor induces lateral segregation of phosphatidic acid and phosphatidylcholine in reconstituted membranes. Biochemistry 44 398–410.

    Not in our library10.1021/bi048026g

  411. 411.

    Whitehouse P. J. Martino A. M. Antuono P. G. Lowenstein P. R. Coyle J. T. Price D. L. (1986 ). Nicotinic acetylcholine binding sites in Alzheimer’s disease. Brain Res. 371 146–151.

    Not in our library10.1016/0006-8993(86)90819-x

  412. 412.

    Whitehouse P. J. Price D. L. Clark A. W. Coyle J. T. DeLong M. R. (1981 ). Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 10 122–126.

    Not in our library10.1002/ana.410100203

  413. 413.

    Whitehouse P. J. Struble R. G. Clark A. W. Price D. L. (1982 ). Alzheimer disease: plaques, tangles, and the basal forebrain. Ann. Neurol. 12:494.

    Not in our library10.1002/ana.410120517

  414. 414.

    Willmann R. Pun S. Sadasivam G. Santos A. F. Caroni P. Fuhrer C. (2006 ). Cholesterol and lipid microdomains stabilize the postsynapse at the neuromuscular junction. EMBO J. 25 4050–4060.

    Not in our library10.1038/sj.emboj.7601288

  415. 415.

    Wonnacott S. Barik J. Dickinson J. Jones I. W. (2006 ). Nicotinic receptors modulate transmitter cross talk in the CNS: Nicotinic modulation of transmitters. J. Mol. Neurosci. 30 137–140.

    Not in our library10.1385/jmn:30:1:137

  416. 416.

    Wood W. G. Li L. Müller W. E. Eckert G. P. (2014 ). Cholesterol as a causative factor in Alzheimer disease: a debatable hypothesis. J.Neurochem. 129 559–572.

    Not in our library10.1111/jnc.12637

  417. 417.

    Wood W. G. Schroeder F. Igbavboa U. Avdulov N. A. Chochina S. V. (2002 ). Brain membrane cholesterol domains, aging and amyloid beta-peptides. Neurobiol. Aging 23 685–694.

    Not in our library10.1016/s0197-4580(02)00018-0

  418. 418.

    Woolf N. J. (1998 ). A structural basis for memory storage in mammals. Prog. Neurobiol. 55 59–77.

    Not in our library10.1016/s0301-0082(97)00094-4

  419. 419.

    Wu J. Khan G. M. Nichols R. A. (2007 ). Dopamine release in prefrontal cortex in response to beta-amyloid activation of alpha7 nicotinic receptors. Brain Res. 1182 82–89.

    Not in our library10.1016/j.brainres.2007.08.079

  420. 420.

    Wu J. Kuo Y. P. George A. A. Xu L. Hu J. Lukas R. J. (2004 ). Beta-Amyloid directly inhibits human alpha4beta2-nicotinic acetylcholine receptors heterologously expressed in human SH-EP1 cells. J. Biol. Chem. 279 37842–37851.

    Not in our library10.1074/jbc.m400335200

  421. 421.

    Wu Y. Luo Y. (2005 ). Transgenic C. elegans as a model in Alzheimer’s research. Curr. Alzheimer. Res. 2 37–45.

    Not in our library10.2174/1567205052772768

  422. 422.

    Xie H. Q. Leung K. W. Chen V. P. Chan G. K. L. Xu S. L. Guo A. J. Y. (2010a ). Chemico-Biological Interactions PRiMA directs a restricted localization of tetrameric AChE at synapses. Chem. Biol. Interact. 187 78–83.

    Not in our library10.1016/j.cbi.2010.02.018

  423. 423.

    Xie H. Q. Liang D. Leung K. W. Chen V. P. Zhu K. Y. Chan W. K. B. (2010b ). Targeting Acetylcholinesterase to Membrane Rafts a function mediated by the proline-rich membrane anchor (PRiMA) in neurons. J. Biol. Chem. 285 11537–11546.

    Not in our library10.1074/jbc.m109.038711

  424. 424.

    Xiong H. Callaghan D. Jones A. Walker D. G. Lue L. F. Beach T. G. (2008 ). Cholesterol retention in Alzheimer’s brain is responsible for high beta- and gamma-secretase activities and Abeta production. Neurobiol. Dis. 29 422–437.

    Not in our library10.1016/j.nbd.2007.10.005

  425. 425.

    Xiu J. Nordberg A. Zhang J. T. Guan Z. Z. (2005 ). Expression of nicotinic receptors on primary cultures of rat astrocytes and up-regulation of the alpha7, alpha4 and beta2 subunits in response to nanomolar concentrations of the beta-amyloid peptide(1-42). Neurochem. Int. 47 281–290.

    Not in our library10.1016/j.neuint.2005.04.023

  426. 426.

    Yahi N. Fantini J. (2014 ). Deciphering the glycolipid code of Alzheimer’s and Parkinson’s amyloid proteins allowed the creation of a universal ganglioside-binding peptide. PLoS One. 9:e104751.

    Not in our library10.1371/journal.pone.0104751

  427. 427.

    Yamamoto N. Hasegawa K. Matsuzaki K. Naiki H. Yanagisawa K. (2004 ). Environment- and mutation-dependent aggregation behavior of Alzheimer amyloid beta-protein. J. Neurochem. 90 62–69.

    Not in our library10.1111/j.1471-4159.2004.02459.x

  428. 428.

    Yamamoto N. Matsubara T. Sato T. Yanagisawa K. (2008 ). Age-dependent high-density clustering of GM1 ganglioside at presynaptic neuritic terminals promotes amyloid β -protein fi brillogenesis. Biochim. Biophys. Acta 1778 2717–2726.

    Not in our library10.1016/j.bbamem.2008.07.028

  429. 429.

    Yamamoto N. Matsuzaki K. Yanagisawa K. (2005 ). Cross-seeding of wild-type and hereditary variant-type amyloid beta-proteins in the presence of gangliosides. J. Neurochem. 95 1167–1176.

    Not in our library10.1111/j.1471-4159.2005.03444.x

  430. 430.

    Yanagisawa K. (2005 ). GM1 ganglioside and the seeding of amyloid in Alzheimer’s disease: endogenous seed for Alzheimer amyloid. Neuroscientist 11 250–260.

    Not in our library10.1177/1073858405275177

  431. 431.

    Yanagisawa K. Ihara Y. (1998 ). GM1 ganglioside-bound amyloid beta-protein in Alzheimer’s disease brain. Neurobiol. Aging 19(1 Suppl.), S65–S67.

    Not in our library10.1177/1073858405275177

  432. 432.

    Yanagisawa K. Odaka A. Suzuki N. Ihara Y. (1995 ). GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer’s disease. Nat. Med. 1 1062–1066.

    Not in our library10.1038/nm1095-1062

  433. 433.

    Yang X. Askarova S. Lee J. C.-M. (2010 ). Membrane biophysics and mechanics in Alzheimer’s disease. Mol. Neurobiol. 41 138–148.

    Not in our library10.1007/s12035-010-8121-9

  434. 434.

    Yankner B. A. Duffy L. K. Kirschner D. A. (1990 ). Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250 279–282.

    Not in our library10.1126/science.2218531

  435. 435.

    Yip C. M. Darabie A. A. McLaurin J. (2002 ). Abeta42-peptide assembly on lipid bilayers. J. Mol. Biol. 318 97–107.

    Not in our library10.1016/s0022-2836(02)00028-1

  436. 436.

    Yu W. F. Guan Z. Z. Bogdanovic N. Nordberg A. (2005 ). High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer’s disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques. Exp. Neurol. 2192 215–225.

    Not in our library10.1016/j.expneurol.2004.12.015

  437. 437.

    Yu X. Zheng J. (2012 ). Cholesterol promotes the interaction of Alzheimer β-amyloid monomer with lipid bilayer. J. Mol. Biol. 421 561–571.

    Not in our library10.1016/j.jmb.2011.11.006

  438. 438.

    Zampagni M. Evangelisti E. Cascella R. Liguri G. Becatti M. Pensalfini A. (2010 ). Lipid rafts are primary mediators of amyloid oxidative attack on plasma membrane. J. Mol. Med. 88 597–608.

    Not in our library10.1007/s00109-010-0603-608

  439. 439.

    Zhang Q. Powers E. T. Nieva J. Huff M. E. Dendle M. A. Bieschke J. (2004 ). Metabolite-initiated protein misfolding may trigger Alzheimer’s disease. Proc. Natl. Acad. Sci. U.S.A. 101 4752–4757.

    Not in our library10.1073/pnas.0400924101

  440. 440.

    Zhu D. Xiong W. C. Mei L. (2006 ). Lipid rafts serve as a signaling platform for Nicotinic Acetylcholine receptor clustering. J. Neurosci. 26 4841–4851.

    Not in our library10.1523/jneurosci.2807-05.2006

  441. 441.

    Zimmerberg J. Gawrisch K. (2006 ). The physical chemistry of biological membranes. Nat. Chem. Biol. 2 564–567.

    Not in our library10.1038/nchembio1106-564

  442. 442.

    Zou K. Gong J. S. Yanagisawa K. Michikawa M. (2002 ). A novel function of monomeric amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage. J. Neurosci. 22 4833–4841.

    Not in our library10.1523/jneurosci.22-12-04833.2002

  443. 443.

    Zou K. Kim D. Kakio A. Byun K. Gong J. S. Kim J. (2003 ). Amyloid beta-protein (Abeta)1-40 protects neurons from damage induced by Abeta1-42 in culture and in rat brain. J. Neurochem. 87 609–619.

    Not in our library10.1046/j.1471-4159.2003.02018.x

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.